





Proteomic Characterization of Novel Protein-Protein 













Yeo Wee Ming 













A THESIS SUBMITTED FOR THE DEGREE OF 
DOCTOR OF PHILOSOPHY 
DEPARTMENT OF MICROBIOLOGY 





Ernest appreciation to the following people: 
 
My supervisor, A/P Vincent Chow, for his understanding, patience and constant guidance. 
 
Lecturers of the Department of Microbiology, especially Prof. Chan Soh Ha, A/P Sim 
Tiow Suan, A/P Poh Chit Laa, A/P Mary Ng and Dr. Wong Siew Heng for their advice 
and encouragements. 
 
All the staff of the Department of Microbiology, especially Lim Ek Wang, Phoon Meng 
Chee and Josephine Howe, for pushing me on when I needed it. 
 
All the staff and students in the Human Genome Laboratory for having gone through the 
ups and downs of the project with me. 
 
My parents for supporting me spiritually and financially before and during my 
embarkment on this research project. 
 
My parent-in-laws for their constant concerns and encouragements. 
 
Cathy and Emma for understanding when I cannot be around during dinner and playtime. 
 
 iii
CONTENTS              Page 
 
TITLE           i 
ACKNOWLEDGEMENTS        ii 
CONTENTS          iii 
LIST OF TABLES         vii 
LIST OF FIGURES         viii 
ABBREVIATIONS         x 
CHAPTER 1: ABSTRACT        11 
CHAPTER 2: LITERATURE REVIEW      12 
CHAPTER 3: MATERIALS AND METHODS     57 
CHAPTER 4: RESULTS AND DISCUSSION     71 
CHAPTER 5: CONCLUSION       106 
CHAPTER 6: REFERENCES       121 
APPENDIX          148 
PUBLICATIONS         151 
INTERNATIONAL CONFERENCES      152 
 
 iv
CONTENTS                Page 
• Chapter 1: Abstract        11 
• Chapter 2: Literature Review       15 
o 2.1 The Yeast Two-Hybrid System     16 
o 2.2 Picornaviruses        21 
 2.2.1 Enterovirus      25 
o 2.3 Herpesviridae        30 
 2.3.1 Betaherpesvirinae      31 
2.3.1.1 Classification and Subtypes    32 
Classification      32 
Subtypes       32 
Host-cell tropism      33 
Receptor interactions     34 
Permissive and latent infections by HHV-6  34 
Effect on T-cells      36 
2.3.1.2 Genetics and molecular biology    36 
Genome Organization and Relationship to other 
Herpesvirus      36 
Viral origin of DNA replication    40 
2.3.1.3 Viral genes      42 
Viral glycoproteins     43 
Other viral genes, including the viral protease  44 
2.3.1.4 Association with disease     47 
Primary infection and association with exanthema 
 
 v
        Page 
subitum (roseola)      48 
Association with neurological disease   49 
       Viral infection of oligodendrocytes and association 
with multiple sclerosis     50 
Association with malignancies    52 
2.3.1.5 Association with disease in immunocompromised 
individuals      52 
Role in chronic fatigue immunodeficiency syndrome 53 
2.3.1.6 Relationship between HHV-6 and HIV-1  54 
2.3.1.7 Clinical implications and applications   55 
Management of severe complications of infection, 
including neurological disease.    56 
• Chapter 3: Materials and Methods      57 
 3.1 Enterovirus 71       58 
 3.1.1 Bacterial and Yeast Transformations    58 
 3.1.2 in vivo protein expression     59 
 3.1.3 Yeast Two-hybrid techniques     60 
 3.1.4 Culturing of mammalian cells     61 
 3.1.5 in vivo transcription/translation assay    62 
 3.1.6 Cellular transfection and translation assays   62 
 3.1.7 Confocal immunofluorescent staining assay   63 





o 3.2 Human Herpesvirus 6      65 
 3.2.1 Bacterial and Yeast Transformations    65 
 3.2.2 in vivo protein expression     66 
 3.2.3 Yeast mating experiment     66 
 3.2.4 Propagation of the numan MT-4 cell line, transfection and co-
immunoprecipitation assays     66 
 3.2.5 Immunofluorescnece confocal microscopy   67 
 3.2.6 Determination of virus titer by TCID50 and assay assay for 
cell viability       68 
 3.2.7 Short hairpin RNA (shRNA) constructs to induce specific 
antiviral response by RNA interference (RNAi)  68 
 3.2.8 Real-time RT-PCR      69 
 3.2.9 Transmission electron microscopy    70 
 3.2.10 Mitochondrial membrane potential assay by flow 
cytometry       70 
Chapter 4: Results and Discussion      71 
4.1 EV71        72 
4.2 U95         88 
• Chapter 5: Conclusion       106 
• Chapter 6: References        121 




LIST OF TABLES         Page 
1. Table 1: Analysis of the frequency of structural abnormalities 
Of mitochondria in HHV-6B–infected versus 
Uninfected MT-4 cells at 0, 1, 4 and 7 h post-infection  97 
2. Table 2: Genetics and cell infection of human herpesvirus 6 
(HHV-6) and human herpesvirus 7 (HHV-7)   110 
3. Table 3: Genetics of human herpesvirus 6 (HHV-6) and 
human herpesvirus 7 (HHV-7)     112 
4. Table 4: Primers designed for use specifically in the Yeast 
Two-Hybrid experiments      119 
5. Table 5: Primers designed for VP1 and U95 in the Yeast 
Two-Hybrid experiments      120
 viii
LIST OF FIGURES 
 Figures         Page 
1. 2.1.1: Principle of the Two-Hybrid system     17 
2. 2.2.1: Cartoon representation of a typical life cycle of Picornavirus 23 
3. 2.2.2: Cartoon representation of the assembly and packaging of a virion 24 
4. 2.2.1.1:Genotypic classification of Enterovirus 71    27 
5. 2.2.1.2 Structure of EV71 genome      28 
6. 2.2.1.3 Typical route of infection, spread and egression of an enterovirus 29 
7. 2.3.1.2.1Genome organization of human herpesvirus 6 (HHV-6) and human 
herpesvirus 7 (HHV-7)      39 
7. 2.3.1.2.2 Schematic diagram of human herpesvirus 6 oriLyt   41 
8. 2.3.1.3.1 Alignment of the protein sequences of the serine proteases of 
human cytomegalovirus (HCMV), human herpesvirus 6 and 
human herpesvirus 7       46 
9. 4.1.1: Gel electrophoresis photographs of colony PCR   74 
10. 4.1.2: β-galactosidase assay       74 
11. 4.1.3: The result for the co-immunoprecipitation of VP1 and Ornithine 
  Decarboxylase 1       75 
12. 4.1.4: The result for the co-immunoprecipitation of VP1 and GTAR 76 
13. 4.1.5: The result for the co-immunoprecipitation of VP1 and KIAA0697  77 
14. 4.1.6: Co-localization of EV71 VP1 with ODC1    78 





Figures         Page 
16. 4.1.8: Co-localization of EV71 VP1 with KIAA0697   80 
17. 4.1.9: Specific detection of wild-type VP1 protein in EV71-infected 
cells         81 
18. 4.1.10: Kinetics of co-localization of wild-type VP1 protein with 
endogenous ODC1 in EV71-infected cells    82 
19. 4.1.11: Negative controls for immunofluorescence studies   83 
20. 4.2.1: Co-immunoprecipitation of HHV-6B U95 and human 
GRIM-19 proteins in MT-4 cells     89 
21. 4.2.2: Intracellular co-localization of HHV-6B U95 with GRIM-19 91 
22. 4.2.3: Co-localization of HHV-6B U95 with endogenous GRIM-19 
in MT-4 cells        92 
23. 4.2.4: Real-time RT-PCR analyses of relative U95 mRNA expression 
levels in HHV-6B-infected MT-4 cells following U95-shRNA 
treatment compared with controls     93 
24. 4.2.5: Transmission electron micrographs of HHV-6B-infected cells 
without and with U95-shRNA treatment    96 
25. 4.2.6: Assessment of mitochondrial membrane potential by the 




aa    amino acids 
BCIP    5-bromo-4-chloro-3-indoyl phophate 
bp    base pairs 
CA16    Coxsackievirus 16 
cDNA    complimentary DNA 
c-Myc    Human oncoprotein 
CPE    Cytopathic effect 
DNA    Deoxyribonucleic Acid 
dNTP    Deoxyribonucleotide triphosphate 
FITC    Fluorescein isothiocyanate 
FLAG    Short DYKDDDDK polypeptide 
HA Short YPY DVP DYA polypeptide from hemagglutinin 
influenza virus 
HFMD Hand, foot and mouth disease 
kb    Kilobase 
KDa    Kilodalton 
lacZ Z gene of lactose operon (encoding the enzyme β-
galactosidaes 
LB Luria Broth 






MOI Multiplicity of infection 
NBT Nitroblue tetrazolium 
ng Nanogram 
nt Nucleotide 
OD Optical density 
ORF Open reading frame 
PAGE Polyacrylamide gel electrophoresis 
PBS Phosphate-buffered saline 
PCR Polymerase chain reaction 
RNA Ribonucleic Acid 
RNase Ribonuclease 
SDS Sodium dodecyl sulphate 
TBST Tris-borate-EDTA Tween 20 
X-gal 5-bromo-4-chloro-3-indoyl-β-galactopyranoside 

















The Yeast-Two Hybrid System is a valuable screening tool for the identification and 
isolation of potential interacting protein partners for your protein of interest. The 
knowledge requirement for your protein of interest is only very minimal. If a protein has 
a known function, new proteins that bind to it bring additional components into play, 
ultimately contributing to understanding the process under study. Alternatively, the 
function of a protein may be obscure but the protein may be of obvious relevance in 
certain hereditary diseases. The best part about the system is its ability to analyze protein 
from any organisms. It is with such interest that the two important human pathogen 
proteins, virus coat protein 1 of Enterovirus 71 and U95 of Human Herpesvirus 6, were 
selected as baits in this research. 
Enterovirus 71 (EV71) is a major etiological agent of hand, foot and mouth disease 
(HFMD). Several outbreaks in East Asia were associated with neurological complications 
and numerous deaths. EV71 possesses four structural proteins VP1 to VP4 that are 
necessary in the formation of the pentameric icosahedral capsid. The viral capsid 
contributes to virulence, and VP1 is a prime target for EV71 vaccine development. Using 
yeast two-hybrid analysis, we demonstrated binding affinity between VP1 and three 
human proteins, i.e. ornithine decarboxylase (ODC1), gene trap ankyrin repeat (GTAR), 
and KIAA0697 expressed in brain tissue. These interactions were authenticated by co-
immunoprecipitation experiments, and by indirect immunofluorescent confocal 
microscopy of transfected and EV71-infected Vero cells. The significant interaction 
between VP1 and ODC1 may compromise the latter’s activity, and interfere with 
polyamine biosynthesis, growth and proliferation of EV71-infected cells. The interaction 
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between VP1 and GTAR is noteworthy since ankyrin proteins are associated with certain 
neural cell adhesion molecules and with the CRASH neurological syndrome. Given that 
VP1 is synthesized in large amounts during productive infection, these viral-host protein 
interactions may provide insights into the role of VP1 in the pathogenesis of EV71 
disease and its neurological complications such as acute flaccid paralysis and encephalitis. 
To better understand the pathogenesis of human herpesvirus 6 (HHV-6), it is 
important to elucidate the functional aspects of immediate-early (IE) genes at the initial 
phase of the infection. To study the functional role of the HHV-6B IE gene, U95, we 
generated a U95-Myc fusion protein, and screened a pre-transformed bone marrow 
cDNA library for U95-interacting proteins using yeast-two hybrid analysis. The most 
frequently appearing U95-interacting protein identified was GRIM-19 which belongs to 
the family of genes associated with retinoid-interferon mortality and serves as an 
essential component of the oxidative phosphorylation system. This interaction was 
verified by both co-immunoprecipitation and confocal microscopic co-
immunolocalization. Short-term HHV-6B infection of MT-4 T-lymphocytic cells induced 
syncytial formation, resulted in decreased mitochondrial membrane potential, and led to 
progressively pronounced ultrastructural changes such as mitochondrial swelling, myelin-
like figures, and loss of cristae. Compared to controls, RNA interference against U95 
effectively reduced the U95 mRNA copy number, and abrogated the loss of 
mitochondrial membrane potential. Our results indicate that the high affinity between 
U95 early viral protein and GRIM-19 may be closely linked to the detrimental effect of 
HHV-6B infection on mitochondria. These findings may explain the alternative cell death 
mechanism of expiration observed in certain productively HHV-6B-infected cells, as 
opposed to apoptosis. The interaction between U95 and GRIM-19 is thus functionally 
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and metabolically significant in HHV-6B-infected cells, and may be a means through 
















2.1 The Yeast Two-Hybrid System 
 
The yeast two-hybrid system is simply the using of yeast cells as biochemical 
reaction “containers” and involves two hybrid fusion proteins interacting in these 
“containers”. Yeast are a group of unicellular fungi in which a few species are commonly 
used to leaven bread and ferment alcoholic beverages. Most yeast strains belong to the 
division Ascomycota. A few yeasts, such as Candida albicans can cause infection in 
humans. More than one-thousand species of yeasts have been described. The most 
commonly used yeast is Saccharomyces cerevisiae, which was used for wine, bread and 
beer production thousands of years ago. The yeast two-hybrid system is a novel way for 
detection of protein-protein interactions in-vivo in Saccharomyces cerevisiae (baker’s 
yeast). As Saccharomyces cerevisiae is an eukaryote and was the first eukaryote to have 
its genome sequenced in 1996, it is the most suitable organism to be employed to 
translate and host interacting eukaryote proteins. 
The basis of this two-hybrid system depends on the structure of particular 
transcription factors that have two physically separable domains: the transcription 
activation domain (AD) and the DNA-binding domain (BD). The DNA-binding domain 
helps to direct the transcription factor to specific promoter sequences (designated 
Upstream Activation Sequence) whereas the activation domain serves to assist assembly 
of the transcription complex thereby allowing initiation of transcription (Figure 2.1.1) . 
The fact that a functional transcription factor can be reconstituted through noncovalent 
interaction of two independent hybrid proteins containing either a DNA-binding domain  
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Fig. 2.1.1. Principle of the Two-hybrid system. (A), (B) Two 
chimeras, one containing the DNA-binding domain (DB: blue 
circle) and one that contains an activation domain (AD: half blue 
circle), are co-transfected into an appropriate host strain. (C) If the 
fusion partners (yellow and red) interact, the DB and AD are 
brought into proximity and can activate transcription of reporter 
genes (here LacZ). 
(Adopted: http://www.biologicalprocedures.com/bpo/arts/1/16/m16.htm) 
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or an activation domain constitutes the basis of the two-hybrid approach (Fields and Song, 
1989). 
Protein-protein interactions are intrinsic to virtually every cellular process ranging 
from DNA replication, transcription, splicing and translation, to secretion, cell cycle 
control, intermediary metabolism, formation of cellular macrostructures and enzymatic 
complexes. Hence to understand every individual functions of a single protein, we need 
to look at the participation of the protein in all the biological pathways; interacting 
proteins might give a functional hint if at least one of the partners has a known functional 
commitment in a well understood biological pathway. The study of protein-protein 
interactions can be conceptually divided into three major domains: identification, 
characterization and manipulation. Traditionally, the tools available to analyze protein-
protein interactions in multicellular organisms have been restricted to biochemical 
approaches in vitro. Biochemical approaches can be time-consuming and that detection of 
proteins that bind to another proteins generally result in the appearance of a band on an 
immobilized matrix. These raw materials are usually derived from a bacterial host, where 
not all post-translational modifications needed for the interaction might occur. Moreover, 
screening rather than selection is used as the means of detection, which inherently limits 
the number of interactors that can be picked up. In contrast to biochemical methods 
detecting protein-protein interaction, this system is based on a eukaryotic system in 
which the proteins generally undergo post-translational modifications, as unlike the 
prokaryotic system. Moreover, this system is based on a yeast genetic assay in which the 
interaction of two proteins is measured by the reconstitution of a functional transcription 
activator in vivo (Fields and Song, 1989, Chien et al, 1991). With this method, mutational 
analysis can also be done to pin-point the exact location of the domains/residues 
necessary for the interaction. Secondly, only the cDNA, full-length or even partial of the 
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gene of interest is needed, in contrast to high quantities of purified proteins or good 
quality antibodies needed in classical biochemical approaches. Moreover, weak and 
transient interactions, often the most interesting in signaling cascades, are more readily 
detected in two-hybrid since the genetic reporter gene strategy results in a significant 
amplification. Thirdly, apart from the ability to screen libraries for unknown interactions, 
the two-hybrid system also allows for the analysis of known interactions. Fourthly, the 
identification of an interacting protein implies that at the same time the corresponding 
gene is cloned. Last but not least, modification of this system has allowed for studies of 
protein-DNA and protein-RNA interactions. 
Knowing the abilities of the system will not allow one to maximize the capabilities of 
the system unless the shortfalls are well understood and addressed during the deployment 
of this system. First and foremost, due to the nature of the system, many false-positives 
will be obtained. Those documented commonly occurring false-positives include heat 
shock proteins, ribosomal proteins, cytochrome oxidase, proteosome subunits, ferritin, 
transfer RNA-synthase, collagen-related proteins, vimentin, inorganic pyrophosphatase 
and transcription factors (Hengen, 1997). Depending on the nature of the bait, many 
clones will be obtained, making the screening process very monotonous and laborious. 
As the cloning of the cDNA library for screening is conducted ramdomly, the cloned 
gene may not be in the correct reading frame and translation may or may not occur, 
depending on if an open reading frame is resulted or not; this is a disadvantage of the 
system as hypothetical proteins could be produced. Finally, contamination of the 
screening library by genomic DNA, having possible open reading frame sequences, 
making screening very discouraging and tedious. 
Deviations from the Yeast Two-Hydrid System have led to the development of new 
systems in actual mammalian environments that have added flexibility and provide novel 
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applications. This is because yeast is a single-celled eukaryote and its genome is much 
smaller than those of mammals, which necessitates that its cellular context differs from 
that of a mammalian cell. The latest development involving looking at protein-protein 
interactions in the mammalian cells, the two-hybrid systems in mammalian cells, can 
ensure that the protein−protein interactions under scrutiny happen in a more 'natural' 
environment. When it comes to studying protein−protein interactions mediating signal 
transduction, the mammalian two-hybrid system has the added advantage of being 




Picornaviruses are viruses belonging to the Picornaviridae. As the name described, 
they are small single-stranded positive-sense RNA viruses (pico means small and rna 
means RNA genome), of between 18-30 nm. The Picornaviridae is divided into nine 
genera, Aphthovirus, Cardiovirus, Enterovirus, Hepatovirus, Parechovirus, Rhinovirus, 
Erbovirus, Kobuvirus and Teschovirus (International Committee on Taxonomy of Virus 
database). They are one of the largest and most important families of human and 
agricultural pathogens, including poliovirus (poliomyelitis), rhinovirus (common cold), 
hepatitis A virus, and foot-and-mouth disease virus (FMDV). Their economic and 
medical importance has led to their prominence in the development of modern virology 
(Rueckert 1996). These viruses can cause an extraordinarily wide range of illnesses. The 
syndromes associated with these agents include asymptomatic infection, colds, febrile 
illness with rash, conjunctivitis, herpangina, muscle infection, myocarditis and 
pericarditis, hepatitis, neurological complications such as neurogenic pulmonary oedema 
and polio-like paralysis, encephalitis and meningitis. Probably no other family of viruses 
causes such a diversity of illness. One member of this family, the poliomyelitis virus, was 
one of the first recorded infections; an Egyptian tomb carving showed a man with a foot-
drop deformity typical of paralytic poliomyelitis. Another member of the picornaviruses 
is the hand-foot-and-mouth disease (HFMD) virus. Bovine foot-and-mouth disease (FMD) 
is caused by a bovine Picornavirus. That virus does not cause HFMD in humans. The 
most common cause of the human syndrome is coxsackievirus A16. 
The viruses of this family all share a similar overall icosahedral capsid structure that 
contains a small positive-sense RNA genome (7.2–8.5 kilobases in length) with a protein, 
VPg, covalently attached to its 5’-terminus and a 3’-terminal poly (A) tail (Oliveira et al, 
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1999). Fig. 2.2.1 shows a typical life cycle of the virus. Their genomes function as 
mRNA on entry into the cytoplasm and are translated to yield all viral polypeptides 
necessary for replication. The 5’ untranslated region (UTR) contains the determinants for 
translation of the viral RNA by internal ribosomal entry site (IRES) mechanism for 
amplification of viral RNA and for neurovirulence (Evans et al, 1985). The 3’ UTR 
region contains a pseudo-knot like structure that is important for replication of viral RNA. 
High-resolution structures of rhinoviruses (Rossmann et al,., 1985), poliovirus (Hogle et 
al,., 1985), and FMDV (Acharya et al,., 1989) have been solved by x-ray diffraction. The 
viral capsid of picornaviruses consists of a densely packed icosahedral arrangement of 60 
protomers, composed of four different proteins (VP1-VP4) each, and the shell is arranged 
on a pseudo T 5 3 symmetry (p 5 3) with a diameter of 27–30 nm. The protein subunits 
are produced from a proteolytic cleavage of the polyprotein (Oliveira et al, 1999). These 
subunits are then assembled into the typical pentameric structure of the virus capsid (Fig. 
2.2.2). The capsid-coat protein serves multiple functions, including: 
(a) protecting the viral RNA from degradation by environmental RNAse, 
(b) determining host and tissue tropism by recognition of cell-specific cell-
membrane receptors, 
(c) penetrating target cells and delivering the viral RNA into the cell cytoplasm, 
and 
(d) selecting and packaging viral RNA. 
All members of this family lack a lipid envelope and, therefore, are resistant to ether, 
chloroform, and alcohol. However, ionizing radiation, phenol, and formaldehyde readily 
inactivate these viruses. If protected from nucleases, naked picornaviral RNA can infect 





Fig. 2.2.1. Cartoon representation of a typical life cycle of Picornavirus. 
(Adopted from Dr. Alan Cann, Tulane University, New Orleans). 
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Fig. 2.2.2. Cartoon representation of the assembly and packaging of a 
virion. (Adopted from Dr. Alan Cann, Tulane University, New Orleans). 
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2.2.1 Enterovirus 
EV71 is a picornavirus assigned to the genus Enterovirus and species Enterovirus A.  
The genotypic classification of enterovirus 71 can be seen in Fig. 2.2.1.1. It is a small, 
non-enveloped, positive-stranded RNA virus with a genome size of about 7.5kb The 
genome comprises a 5’ UTR, a long open reading frame that encodes a protein of 
approximately 2100 amino acid residues, a short 3’ UTR and a poly adenylated tail (Fig. 
2.2.1.2). It has a characteristic pentameric isocahedral outer capsid. The capsid is made 
up of 60 copies each of four structural proteins VP1-4 (Ranganathan et al, 2002). The 
viral capsid is known to contribute significantly to the pathogenicity of the virus. An X-
ray crystallography has shown that the icosahedral capsid enclosing the RNA genome is 
roughly 5 nm thick and 30 nm in diameter (Reukert 1996). Enteroviruses can survive a 
wide pH range of 2-10. It is this stability in acid that allows the virus to be ingested and 
safely reach the intestinal tracts of animals, where the small intestines are the major 
invasion site of enteroviruses (Levy et al, 1994) (Fig. 2.2.1.3). Moreover, it was found 
that certain enterovirus, like poliovirus, is stable to high pressure at room temperature, 
because pressures up to 2.4 kbar are not enough to promote viral disassembly and 
inactivation. Poliovirus can achieve complete dissociation only at 2.4 kbar in the presence 
of subdenaturing concentrations of urea (1–2 M) and at low temperature (-15°C), 
producing inactivated particles (Oliveira et al, 1999). 
The disease caused by the enterovirus 71 has commonly been known as the Hand, 
Foot and Mouth Disease (HFMD). The infected person usually shows mild fever, poor 
appetite, malaise ("feeling sick"), and frequently a sore throat. One or 2 days after the 
fever begins, painful sores develop in the mouth. They begin as small red spots that 
blister and then often become ulcers. They are usually located on the tongue, gums, and 
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inside of the cheeks. The skin rash develops over 1 to 2 days with flat or raised red spots, 
some with blisters. The rash does not itch, and it is usually located on the palms of the 
hands and soles of the feet and hence, the name Hand, Foot and Mouth Disease. 
Pathologic studies showed extensive inflammation in the central nervous system (CNS), 
with predominant lesions in the brain stem and spinal cord (Hsueh et al, 2000). Marked 
pulmonary edema with focal hemorrhage occurred without evidence of myocarditis.  
The most recent major outbreak in Asia is in Taiwan in 1998, where most patients 
with cardiopulmonary failure died (Ho et al, 1999; Chang et al, 1999). Most enterovirus 
infections during pregnancy cause mild or no illness in the mother. At present, there is no 
clear evidence that maternal enteroviral infection causes adverse outcomes of pregnancy 
such as abortion, stillbirth, or congenital defects. However, mothers infected shortly 
before delivery may pass the virus to the newborn. Babies born to mothers who have 
symptoms of enteroviral illness around the time of delivery are more likely to be infected. 
Most newborns infected with an enterovirus have mild illness, but, in rare cases, they 
may develop an overwhelming infection of many organs, including liver and heart, and 
die from the infection. The risk of this severe illness in newborns is higher during the first 






Fig. 2.2.1.1. Genotypic classification of enterovirus 71. The vertical bar connecting virus pairs 
represents the percentage nucleotide identity of the aligned coat protein sequences, i.e., there is only 
28% identity in the coat protein between hepatovirus and any other enterovirus genus but there is 
60% identity between the two cardiovirus genus listed. Based on the nucleotide sequence identity, 











Structure of EV71 Genome
3B
  Fig. 2.2.1.2. 
P1 P2 P3 
  Picornavirus genomic RNA is infectious. The 5’ UTR contains secondary structure 
  (IRES) while the 3’ UTR is important for (-) strand RNA synthesis. 




Fig. 2.2.1.3. Typical route of infection, spread and egression of an enterovirus. 
(Adopted from Dr. Alan Cann, Tulane University, New Orleans). 
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2.3 Herpesviridae 
The Herpesviridae consists of three subfamilies of virus, the alphaherpesvirinae, 
betaherpesvirinae and gammaherpesvirinae. A typical herpesvirion consists of a core 
containing a linear, double stranded DNA; an icosahedral capsid, approximately 100-110 
nm in diameter, containing 162 capsomeres with a hole running down the long axis; an 
amorphous, sometimes asymmetric material that surrounds the capsid, designated as the 
tegument; and an envelope containing viral glycoprotein spikes on its surface (Roizman 
et al, 1990). There are at least eight human herpesviruses that have been know and 
described. These include: the Herpes simplex virus type 1 (HHV-1), Herpes simplex 
virus type two (HHV-2), Varicella zoster virus (VZV or HHV-3), Cytomegalovirus 
(CMV or HHV-5), Epstein-Barr virus (EBV or HHV-4), Human herpesvirus 6 (HHV-6), 
Human herpesvirus 7 (HHV-7) and Kaposi's sarcoma-associated herpesvirus (HHV-8) 
(ICTVdb 10/2002). 
Within the Herpesviridae, Alphaherpesvirinae is an extensive subfamily which 
contains numerous mammalian and avian viruses includes Herpes Simplex Virus-1 and 2, 
which cause oral conjunctival, central nervous system, genital gingivostomatitis, intense 
pharyngitis, tonsillitis and generalized disease, and Varicella-Zoster Virus, which causes 
chicken pox and shingles. The presence of inverted repeats in the alphaherpesvirus 
genomes allows segment inversion as a consequence of specific recombination between 
repeated sequences during DNA replication (Thiry et al, 2004). Recombination 
frequently occurs between strains of the same alphaherpesvirus species. Interspecific 
recombination depends on enough sequence similarity to enable recombination between 
distinct alphaherpesvirus species. The most important prerequisite for successful 
recombination is co-infection of the individual host by different virus strains or species 
(Thiry et al, 2004). 
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The Betaherpesvirus subfamily contains the genera Human Herpesvirus 6, Human 
herpesvirus 7, Cytomegalovirus (HCMV) and Muromegalovirus (MCMV). These viruses 
have a long reproductive cycle and the infection progresses slowly in culture. Very 
frequently, the infected cells become enlarged (cytomegalia), and carrier cultures are 
readily established. It is possible to maintain the virus in latent form in secretory glands, 
lymphoreticular cells, kidneys, and other tissues. A nonexclusive characteristic of the 
members of this subfamily is a restricted host range. (Roizman et al, 1990) 
The experimental host range of the members of the Gammaherpesvirus subfamily is 
limited to the family or order to which the natural host belongs. All known members are 
able to replicate in lymphoblastoid cells in vitro, cell-specific and some can cause lytic 
infections in some types of epithelioid and fibroblastic cells. Viruses belonging to this 
group are specific for either T or B lymphocytes. In the lymphocyte, infection is 
frequently either at a pre-lytic or lytic stage, but without production of infectious progeny 
and latent virus is frequently demonstrated in lymphoid tissue. Gammaherpesvirinae 
contains the genus Human Herpesvirus 8, Lymphocryptovirus, including EBV, and 
Rhadinovirus (herpesvirus ateles and herpesvirus saimiri) (Cooper et al, 1994; Roizmanet 
et al, 1990). 
 
2.3.1 Betaherpesvirinae 
The first HHV type 6 was isolated from the peripheral blood mononuclear cells of six 
adults with lymphoproliferative disorders, some of whom were infected with human 
immunodeficiency virus type 1 (HIV-1) (Salahuddin et al, 1986). This virus, which was 
initially named human B-lymphotropic virus, or HBLV, was the first new human 
herpesvirus to be identified since the discovery of Epstein-Barr virus over 20 years earlier. 
 32
HHV-6 is an opportunistic viral pathogen that has been shown to be the major cause of 
often life-threatening illness in pediatric and transplant patients. A substantial body of 
scientific evidence points HHV-6 as the culprit of chronic diseases such as multiple 
sclerosis. 
2.3.1.1 Classification and Subtypes 
Classification 
According to a phylogenetic study done by Moore et al in 1996, HHV-6 is most 
closely related to HHV-7 among all the known herpesviruses; next comes human 
cytomegalovirus (HCMV). This genetic similarity in combination with commonalities in 
the biological properties of HHV-6 and HCMV (such as lymphotropism and a slow 
replicative cycle), has prompted the International Committee on Viral Taxonomy 
(http://www.ncbi.nlm.nih.gov/ICTV/index.html) to classify HHV-6 under the beta 
herpesvirus subfamily (genus Roseolovirus).  
Subtypes 
There are two distinct variants of HHV-6, HHV-6A and HHV-6B, and the two 
variants can be distinguished by differences in their antigenicity and biologic properties 
(Pellett et al, 1996). In addition, the viral genomes differ by approximately 4–6% at the 
nucleotide level (Lindquester et al, Gompel et al, 1995); this compares with a much 
lower level of nucleotide divergence (approximately 1%) between different strains of the 
same virus variant.  
Despite the high overall level of sequence homology between HHV-6A and HHV-6B, 
several loci show more extensive sequence divergence. This is illustrated by the presence 
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of numerous open reading frames (ORFs) in which there is at least 10% difference in 
predicted amino acid content between the two variants (Lindquester et al, 1997, Gompel 
et al, 1995). The significance of these localized differences remains a debate. 
HHV-6A and B also differ in other respects. First is the difference in their geographic 
distributions. In North America, HHV-6A was detected in the peripheral blood 
mononuclear cells (PBMC) of less than 3% of children who had acute febrile illness 
resulting from HHV-6 (Dewhurst et al, 1993); whereas in Central Africa, this same 
variant was present in 44% of PBMC samples collected from infants with a first febrile 
episode resulting from HHV-6 (Kasolo et al, 1997). Second, the two variants infect 
distinct tissue compartments, consistent with differences in their in vitro host cell range 
(Pellett et al, 1996). For example, in North America, HHV-6A has been commonly 
identified in lung tissues of both healthy and diseased adults, even though it is rare in the 
PBMC of this population (Cone et al, 1996). Third, the variants differ in their relative 
potential for pathogenicity or their reactivation properties. For example, HHV-6A was 
found to be the predominant HHV-6 variant in lymph nodes from HIV-1 infected adults 
(Knox et al, 1996). Also, the frequency of detection of HHV-6A DNA in PBMC from 
adults with Chronic Fatigue Syndrome (CFS) was found to be significantly higher than in 
PBMC from healthy adults (Di Luca et al, 1995). Clearly, additional studies are required 
to adequately determine the prevalence, anatomic and geographic distribution, and 
pathogenicity of HHV-6. 
Host cell tropism 
Isolates of HHV-6 have been shown to replicate in a wide array of host cell types, 
including primary T cells, monocyte/macrophages, natural killer (NK) cells and 
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astrocytes, but with varying efficiency. Replication can also occur in various cultured cell 
lines of T cell, B cell, megakaryocyte and glial cell lineages (Pellett et al, 1996). In 
general, the host cell range of laboratory-adapted isolates of HHV-6A appears to be 
somewhat broader compared to that of HHV-6B. 
Receptor interactions 
The best binding events involved in herpesvirus infection are known for the 
prototypic human herpesvirus, herpes simplex virus type 1 (HSV-1). Infection is believed 
to occur via an initial interaction with cell surface heparan sulphate proteoglycans 
(HSPGs), followed by binding to a specific cellular receptor. For many strains of HSV-1, 
this receptor is a membrane protein known as the herpesvirus entry mediator (HVEM) 
(Montgomery et al, 1996), which is a member of the tumor necrosis factor receptor 
superfamily.  
In the case of HHV-6, little is known about the events that are involved in virus 
attachment to host cells. At present, only CD46 was found to be crucial for HHV-6 entry 
into the host cells (Santoro et al, 1999); there may be more than one cellular receptors 
involved in the virus’s entry into cells. 
Permissive and latent infections by HHV-6 
CD4+ T cells constitute the major population of cells within tissue cultured PBMC 
that are permissive for replication of both HHV-6A and HHV-6B despite the fact that 
HHV-6 does not bind directly to the cellular CD4 molecule. In addition, cellular 
activation (i.e. mitogenic stimulation of resting T cells) appears to be important for 
efficient virus production.  
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Once HHV-6 enters a permissive host cell, virus replication occurs quite slowly and 
the cells undergo cytopathic effects (CPE) within 3–5 days after infection; changes 
include membrane blebbing, swelling and induction of multinucleated cells (syncytia). 
Ultimately, productive infection of cultured PBMC with HHV-6 results in apoptosis of 
CD4+ T cells, with cell death occurring predominantly in virus-negative bystander cells, 
as has been reported for HIV-1 infection (Inoue et al, 1997).  
Non-permissive and latent infection of host cells by HHV-6 remains less well 
understood than productive infection, and there is currently no adequate in vitro model 
for in vivo latency. However, one study suggested that HHV-6 might be capable of 
establishing a reactivable latent state in cultured monocytes (Kondo et al, 1991). Also, 
targeted integration of HHV-6 genomes has been reported in freshly isolated PBMC from 
three patients with lymphoproliferative disorders, who had unusually high copy numbers 
of viruses in their PBMC (Torelli et al, 1995). It must be noted, however, that the 
integration of herpesviruses into host genomes is generally considered to be very unusual, 
which does not represent a means for herpesvirus latency. As such, the significance of 
integrated forms of the HHV-6 genome remains unclear; although viral reactivation from 
an integrated latent state has been demonstrated for Marek’s disease virus, which is a T-





Effect on T cells 
In addition to the induction of apoptosis, prolific HHV-6 infection has a variety of 
effects on T cells. These include viral-induced changes in the production of many 
cytokines, as well as changes in the expression of cell surface proteins involved in T-cell 
signaling. For example, HHV-6 (HHV-6A and HHV-6B) has been reported to cause the 
de novo expression of CD4 on cells of haematopoietic lineage that are ‘normally’ CD4– , 
such as NK cells, CD8+ T cells and lymphomyeloid progenitor cells (Lusso et al, 1991, 
Lusso et al, 1993, Furlini et al, 1996). In addition, the U1102 and GS strains of HHV-6A 
have been demonstrated to cause downregulation of cell surface CD3 expression (Lusso 
et al, 1991, Furukawa et al, 1994). This might contribute to the reported 
immunosuppressive effects of HHV-6, including its ability to suppress T-cell 
proliferation and T-cell function (Flamand et al, 1995, Horvat et al, 1993). However, it 
remains unclear whether HHV-6B also down-modulates CD3, because the Z29 strain of 
HHV-6B failed to inhibit CD3 expression (Furukawa et al, 1994). Studies of other strains 
of HHV-6B will be needed to determine if this observation is typical for all isolates of 
HHV-6B, or whether it is a strain-specific anomaly, unique to just Z29. 
2.3.1.2 Genetics and molecular biology 
The genetics of HHV-6 are discussed below, and are summarized in Table 2 and 
Table 3. 
Genome organization and relationship to other herpesviruses 
HHV-6 is a beta-herpesvirus that is co-linear with HCMV over most of its genome. 
However, it was noted that the virus also shares a number of genetic properties with the 
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alpha-herpesviruses, and have concluded that the HHV-6 genome might be closest to a 
‘progenitor herpesvirus’, among the currently known herpesviruses of vertebrates (Karlin 
et al, 1994). The conservation of genetic features between HHV-6 (a beta-herpesvirus) 
and alpha-herpesviruses, such as HSV-1, might provide insights to some of the observed 
biologic properties of HHV-6, including its relatively broad host range and its ability to 
cause neurological disease. 
The genome of the U1102 strain of HHV-6A has been completely sequenced and 
consists of a unipartite double-stranded DNA molecule of roughly 159 kb in length, 
which comprises a long unique region (143 kb) bounded at both ends by a direct repeat 
(DR) element of approximately 8 kb (Gompel et al, 1995). This is shown schematically 
in Fig. 2.5.1, which also summarizes some of the other prominent features of the HHV-6 
genome (note that the HHV-6A and HHV-6B genomes appear to be essentially identical 
in terms of their overall organization and structure) (Lindquester et al, 1996).  
The HHV-6 genome is co-linear over much of its length with the genome of HCMV 
(Gompel et al, 1995). This region of overall co-linearity is interspersed with genes found 
only in HHV-6 (and not in HCMV), but can be broadly divided into two major sequence 
‘blocks’. These comprise a central core region (core, Fig. 2.3.1.2.1) that contains genes 
found in all known members of the herpesvirus family (approximately 86 kb in length), 
and a DNA segment (b, Fig. 2.3.1.2.1) that contains genes, thus far, found only in the 
beta-herpesviruses (i.e. in human and murine CMV, and in HHV-6 and HHV-7). The 
DNA segment at the right end of the long unique component of the HHV-6 genome is 
more divergent, and encodes a number of proteins that might be relevant to the biological 
properties of these viruses, including the gp105 glycoprotein (see below) and the major 
immediate-early transactivating proteins. 
 38
The direct repeats that bracket the unique segment of the HHV-6 genome are also 
specific to HHV-6 and HHV-7, and represent regions of genetic divergence from the 
other beta-herpesviruses. The first (non-coding) exon and putative promoter elements for 
the gp105 glycoprotein map to the DR elements, but relatively few other genes appear to 
be encoded here (Gompel et al, 1995, Pfeiffer et al, 1993, Pfeiffer et al, 1995). However, 
the DRs contain a number of important cis-acting DNA elements. The viral genomic 
termini (left and right ends of the DRs) merit special mention because they contain 
consensus sequence motifs (pac-1, pac-2), which have been shown to be involved in the 
cleavage and packaging of replicated herpesvirus genomes (Thomson et al, 1994). In 
addition, human telomeric repeat sequences (TRS; [GGGTTA]n) have been mapped 





Figure 2.3.1.2.1. Genome organization of human herpesvirus 6 (HHV-6) and human herpesvirus 7 
(HHV-7). The overall genome organization of HHV-6 is shown, and the structure of the genomic termini 
of HHV-6 and HHV-7 is also presented. Numbers in the upper portion of the figure refer to nucleotide 
position, in kilobases (kb), within the HHV-6 genome, while numbers in the lower portion of the figure 
refer to nucleotide position, in base pairs (bp), relative to the viral genomic terminus (left or right), which is 
indicated by the arrowheads. The region of co-linearity between HHV-6 and HCMV is indicated at the top 
of the figure, and the conserved sequence blocks (b, core) are discussed in the main text. Other indicated 
DNA motifs include the viral direct repeats (DR), located at the left and right genome ends, as well as 
consensus sequence motifs (pac-1, pac-2) involved in the cleavage and packaging of replicated viral DNA. 
TRS motifs refer to blocks of human telomeric repeat sequences ([GGGTTA]n). Distinct iterations of these 
motifs occur close to the genome ends of HHV-6 and HHV-7 (TRS1, TRS2), including long, 
heterogeneous arrays (long, het.), perfect tandem repeats (tandem array) or short, imperfect arrays (short, 
imperfect) (Adopted from Stephen Dewhurst, Department of Microbiology and Immunology, and Cancer 
Center, University of Rochester Medical Center).  
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These TRSs are present either as perfect tandem hexameric repeats (right terminus of 
HHV-6), or as interrupted imperfect repeat arrays (left terminus of HHV-6), which can 
exhibit significant inter-strain heterogeneity. The functional significance of these TRS 
arrays remains uncertain.  
Viral origin of DNA replication 
The origin of lytic-phase DNA replication (oriLyt) in HHV-6 is located at the same 
locus as the HCMV oriLyt element, immediately downstream of the gene coding for the 
major DNA binding protein (Dewhurst 1993). Despite this common location, HHV-6 
oriLyt has almost no genetic similarity to its HCMV counterpart.  
The structure of HHV-6 oriLyt is shown schematically in Fig. 2.3.1.2.2. It consist a 
central region that is crucial for DNA replication (minimal ori), and which contains 2 
binding sites for an adenine–thymine (AT)-rich spacer sequence as well as a virally-
encoded homologue of the HSV-1 origin-binding protein (OBP); this is much like the 
origins of DNA replication found in all of the alpha-herpesviruses (Inoue et al, 1994). 
HHV-6 oriLyt exhibits additional complexity, however, because the minimal ori is 
flanked by auxiliary sequences that enhance replication efficiency (Dewhurst et al, 1993). 
The most potent of these lies 3' to the minimal ori, and contains two copies of a DR 
element, approximately 200 base pairs (bp) in length; this is predicted to be helically 
unstable and might be functionally analogous to the DNA-unwinding elements (DUE) 




Figure 2.3.1.2.2. Schematic diagram of human herpesvirus 6 (HHV-6) oriLyt. The location 
and structural arrangement of the HHV-6 oriLyt element are shown; all numbers refer to the 
nucleotide position within the HHV-6 genome. As indicated in the upper portion of the figure, 
HHV-6 oriLyt is located in an intergenic region between the U41 and U42 open reading frames 
(ORFs) of the virus [U41 encodes the putative major DNA-binding protein (MDBP) of the virus]. 
The intergenic region, containing the origin, is shown in detail in the lower portion of the figure. 
This region includes two binding sites for the HHV-6 origin-binding protein (OBP), separated by 
an adenine–thymine (AT)-rich spacer. Together, these elements comprise the minimal essential 
origin element (minimal ori). Immediately adjacent to this domain lie two copies of a repetitive 
sequence block of roughly 200 base pairs (bp) in length, which corresponds to a putative DNA 
unwinding element (DUE). This larger domain (minimal efficient ori) replicates with markedly 
higher efficiency than the minimal essential origin element. 
(Adopted from Stephen Dewhurst, Department of Microbiology and Immunology, and Cancer 
Center, University of Rochester Medical Center). 
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2.3.1.3 . Viral genes 
Genes associated with viral DNA replication 
HHV-6 contains homologues of the six core herpesvirus replication genes; these 
encode the viral DNA polymerase (U38), polymerase accessory/processivity protein 
(U27), single-stranded DNA binding protein (U41), and the three helicase-primase 
proteins (U43/U74/U77) (table 2). HHV-6 also possesses a gene (U73) that encodes an 
OBP that is similar to HSV-1 OBP. The presence of this locus within the HHV-6 genome 
was somewhat unexpected because HCMV does not encode a similar protein, but its 
functional relevance became apparent once the structure of HHV-6 oriLyt was known 
(Inoue et al, 1994). 
In addition to the genes described above, HHV-6 also contains a number of other loci 
that might be important for viral DNA replication. These include homologues of three 
genes that are not found in HSV-1, but which have been shown to play a role in the 
replication of HCMV [HCMV open reading frames (ORFs) UL84, UL112 and UL113, 
which correspond to HHV-6 ORFs U55, U79 and U80, respectively; Pari et al, 1993]. 
HHV-6 also encodes a homologue of the adeno-associated virus 2 (AAV-2) rep gene 
(ORF U94) (Gompel et al, 1995, Thomson et al, 1991). This represents a highly unusual 
example of the ‘pirating’ of a gene from one virus by another, unrelated virus. Its 
significance, however, is unclear. In AAV, the Rep protein plays an active role in viral 
gene regulation and DNA replication; it possesses helicase and endonuclease activities 
and exhibits sequence-specific DNA binding activity. The HHV-6 Rep homologue can 
also regulate transcription from a variety of promoter elements, and it can complement 
the replication of a rep-deficient AAV-2 genome (Araujo et al, 1995, Thomson et al, 
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1994). Thus, the HHV-6 rep gene product appears to have conserved at least some of the 
functions of its AAV-2 counterpart, although it remains to be determined whether this 
gene plays a role in HHV-6 DNA replication. 
The betaherpesviruses have extensive domains of similar genetic organization, the 
conserved herpesvirus gene blocks, in the unique region of their genome, and they 
include a number of gene families that are characteristic of this subgroup (Chee et al, 
1990). These include the US22, G-protein-coupled receptor, and immunoglobulin gene 
families. The US22 gene family is the most extensive family found in betaherpesviruses 
but is absent in the alpha- and gammaherpesviruses. HHV-6 encodes 11 members of the 
US22 family, DR1, DR2, DR6, DR7, U2, U3, U7, U8, U16, U25, and U95, which are 
related to the 12 members of this family found in HCMV (Gompel et al, 1995, Neipel et 
al, 1991, Thomson et al, 1992). Some members of this family are spliced and expressed 
as immediate-early (IE) proteins (Kouzarides et al, 1998, Nicholas et al, 1994) and are 
likely to be transcriptional activators (Colberg-Poley et al, 1992, Geng et al, 1996, 
Stasiak et al, 1992, Thomson et al, 1994). Murine cytomegalovirus (MCMV) IE2 has all 
of these characteristics (Cardin et al, 1995, Koszinowski et al, 1986, Messerle et al, 
1991). Since HHV-6 U95 is the positional homolog of MCMV IE2 and has amino acid 
similarity, it has been expected to be expressed as an IE gene (Gompel et al, 1995) and 
therefore, the interest and subject in this study. 
Viral glycoproteins 
In HSV-1, five virion glycoproteins have roles in viral entry: gB, gC, gD, and gH/gL. 
Of these, only four are essential for virus infection (gC is dispensable). HSV-1 gB binds 
to cell surface proteoglycans involved in entry, while HSV-1 gD corresponds to the major 
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receptor-binding protein (Whitbek et al, 1997) and HSV-1 gH/gL are involved in the 
post-attachment penetration of virus, via a process of membrane fusion. Because HHV-6 
encodes homologues of only gB, gH and gL (Gompel et al, 1995), it is possible that 
another, as-yet unidentified, virion component is responsible for receptor binding by 
HHV-6. A potential candidate for this putative receptor-binding protein is the unique 
glycoprotein complex, designated gp82-105, which represents a major component of 
HHV-6 virion and a target for virus-neutralizing antibodies (Pfeiffer et al, 1993,Pfeiffer 
et al, 1995); it is encoded by highly spliced mRNAs that derive from the right end of the 
unique segment of the viral genome (ORFs U96–U100; table 2).  
In addition to gp82-105, HHV-6 also contains a number of other unique ORFs that 
are predicted to encode glycoproteins (table 2). Perhaps the most intriguing of these 
ORFs is U85. This ORF is also conserved in KSHV and in HHV-7, but not in other 
human herpesviruses; it is homologous with the cellular OX-2 gene, which encodes a cell 
surface protein that has recently been shown to possess co-stimulatory activity for resting 
(quiescent or unstimulated) T cells (Borriello et al, 1997). It is, therefore, possible that 
the U85 gene product might play a role in viral evasion of host immune responses, 
although further studies will be required to test this hypothesis. 
Other viral genes, including the viral protease 
HHV-6 contains two ORFs (U12, U51) that are predicted to encode homologues of 
G-protein-coupled receptors, as well as a number of genes that represent potential targets 
for antiviral drugs. These include the viral DNA replication proteins (see above) as well 
as the following proteins:  
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(1) U69, which encodes a putative phosphotransferase (ganciclovir kinase; a 
homologue of HCMV UL97),  
(2) U28, which encodes the large subunit of ribonucleotide reductase and 
(3) U53, the viral protease. The viral protease is of particular interest, because the 
crystal structure of the HCMV protease has recently been determined by independent 
groups of researchers working at four different pharmaceutical companies (Shieh et al, 
1996, Qiu et al, 1996, Tong et al, 1996, Chen et al, 1996).  
Briefly, all herpesviruses encode serine proteases with similar substrate specificity 
(they all cleave a peptide bond between a serine and an alanine). These enzymes perform 
a proteolytic cleavage that is essential for virion maturation and, consequently, they 
represent attractive molecular targets for antiviral drug development.  
Unusual aspects of herpesvirus proteases include the fact that these enzymes are 
catalytically inefficient compared with archetypal serine proteases. They are also only 
weakly inhibited by common serine protease inhibitors, such as phenylmethylsulphonyl 
fluoride (PMSF) and N-tosyl-L-leucine chloromethyl ketone (TLCK). These biochemical 
characteristics might be related to the unique structural properties of this class of enzyme, 
as exemplified by the novel polypeptide backbone fold and active site found in HCMV 
protease. Similarities between the serine proteases of HHV-6 and HCMV include an 
overall level of 42% amino acid identity, as well as the conservation of the His–Ser–His 
catalytic triad, represented by amino acid residues His63, Ser132 and His157 of HCMV 
protease, and by residues His46, Ser116 and His135 of the HHV-6 protease (Fig. 




Figure 2.3.1.3.1. Alignment of the protein sequences of the serine proteases of human 
cytomegalovirus (HCMV), human herpesvirus 6 (HHV-6) and human herpesvirus 7 (HHV-7). The 
sequence motifs in the boxes represent the conserved domains within herpesvirus proteases that are 
described in the main text. Within these boxed regions, the residues shown in red / bold represent amino 
acids that are shared by HCMV, HHV-6 and HHV-7. The three active-site residues are ‘boxed’ in orange 
(in HCMV: Ser132, His63 and His157; in HHV-6: Ser116, His46 and His135; in HHV-7: Ser115, His47 
and His131). Overall, at the amino acid level, the HHV-6 protease is 42% identical to the HCMV protease, 
and 60% identical to the HHV-7 protease. (Adopted from Stephen Dewhurst, Department of Microbiology 




2.3.1.4 Association with disease 
The pathogenesis and epidemiology of HHV-6 infection are discussed below, and are 
summarized in Table 2. 
Ubiquity and persistence 
Serologic surveys have shown that HHV-6 infection occurs in most children by the 
age of three years (Pellett et al, 1996). It is generally assumed that this childhood 
infection is followed by lifelong persistence of the virus, and that this accounts for the 
very high (>90%) seroprevalence of HHV-6 in otherwise healthy adults.  
HHV-6 DNA can be detected in saliva and in PBMC from 90% of healthy individuals 
(Cone et al, 1993); in one study of healthy European adults, HHV-6B was the 
predominant variant detected (Aberle et al, 1996). Quantitative measurements of virus 
load have shown that HHV-6 DNA typically persists in immunocompetent adults at a 
level of approximately 100–4000 viral DNA genome equivalents for every one million (1 
x 106) PBMCs (Cone et al, 1993, Clark et al, 1996). However, some healthy individuals 
can ‘tolerate’ much higher virus loads without apparent ill effects; for example, one 
person examined by Clark and colleagues had a stable burden of roughly 10 x 106 copies 
of HHV-6 DNA for every 1 x 106 PBMCs (Clark et al, 1996). 
The presence of HHV-6 DNA in saliva, and in salivary glands and bronchial glands, 
as well as the finding that infectious HHV-6 can be isolated from specimens of saliva, 
strongly suggest that the virus might be spread horizontally (from one person to another) 
via oral secretions (Pellett et al, 1996). In contrast, vertical transmission of virus (from 
mother to fetus), if it occurs, is rare; perinatal acquisition (infection at or around birth) 
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remains a possibility, in light of studies showing that HHV-6 DNA can be detected in 
secretions from the cervix (Pellett et al, 1996).  
Primary infection and association with exanthem subitum (roseola) 
Yamanishi and co-workers provided the first compelling evidence that primary HHV-
6 infection might be associated with human disease, when they showed that HHV-6 could 
be isolated from the PBMC of 4/4 Japanese infants with exanthem subitum (commonly 
known as roseola) (Yamanishi et al, 1988). Subsequent studies confirmed this association, 
but also noted that primary HHV-6 infection frequently occurs in the absence of the 
diffuse rash that is diagnostic for roseola. Complications of primary viral infection can 
include otitis media (inflammation of the middle ear) and seizures, as well as occasional, 
more serious, disorders such as hepatitis, encephalitis (inflammation of the brain 
substance) and very rare cases of fatal, disseminated infection (Prezioso et al, 1992). 
Awareness of the existence of two distinct viral variants prompted a re-examination 
of the association between HHV-6 and febrile disease of children. In North American, 
European and Japanese infants, the predominant viral variant isolated from peripheral 
blood at the time of acute illness has been HHV-6B (Pellett et al, 1996), although at least 
one case of roseola as a result of primary HHV-6A infection has been reported in a 
Japanese infant (Hidaka et al, 1997). Further studies will be needed to determine the 
timing, presentation and sequelae of primary infection with HHV-6A. 
 
 
Association with neurological disease 
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Several studies have noted that primary HHV-6 infection is a frequent cause of febrile 
convulsions in young children (Pellett et al, 1996), and HHV-6 infections have been 
shown to account for as much as one-third of all febrile seizures in children up to the age 
of two years (Hall et al, 1994). More serious neurological complications of acute HHV-6 
infection can include encephalitis, which has also been described in healthy and 
immunosuppressed adults (Drobyski et al, 1994, Asano et al, 1992, McCullers et al, 
1995). Demyelinating central nervous system (CNS) disease can also occur in some cases 
(Knox et al, 1995, Novoa et al, 1997). 
The propensity for HHV-6 to cause febrile seizures and other neurological illnesses 
might be linked to the neurotropic and neuroinvasive properties of the virus, 
characteristics that HHV-6 shares with HSV-1. HHV-6 DNA has been found at a high 
frequency in brain tissue from apparently healthy adults and in cerebrospinal fluid from 
children during and after acute infection with HHV-6, which suggests that the virus may 
be capable of persisting in the CNS (Caserta et al, 1994, Challoner et al, 1995).  
In most cases examined to date, HHV-6B appears to be the predominant viral variant 
found in the CNS (Aberle et al, 1996, Hall et al, 1994). However, these studies have 
focused principally on Japanese, North American or European children. Thus, the 
relatively infrequent detection of HHV-6A in the CNS could simply reflect the scarcity of 
this viral variant in these countries (Kasolo et al, 1997). Further studies will be needed to 
address this issue. 
 
Viral infection of oligodendrocytes and association with multiple sclerosis 
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The issue of CNS infection by HHV-6 has been studied further using DNA in situ 
hybridization and immunohistochemical staining methods, to determine which cell type(s) 
in the CNS harbor the virus. These studies have shown that HHV-6 DNA is frequently 
localized to oligodendrocytes, at least in the CNS of HIV-1-infected children (Saito et al, 
1995). In adults with multiple sclerosis (MS), structural antigens of the virus have also 
been localized to oligodendrocytes, with expression levels being highest within active 
disease plaques (Challoner et al, 1995). These findings, combined with the absence of 
HHV-6 antigen in oligodendrocytes from control brains (i.e. brains from non-MS 
affected humans), have led to the suggestion that HHV-6 might be associated with the 
aetiology or pathogenesis of MS (Challoner et al, 1995). Several studies have found 
indicators of the virus to be significantly higher in people with MS (PwMS) than in 
control subjects. This link is controversial - some commentators allege that HHV-6 is the 
cause of the disease, others that it is merely an opportunist invader, while still others 
discount its role altogether. People with multiple sclerosis have been found to have higher 
levels of anti-HHV-6 antibodies than control subjects (Caselli et al,, 2002 and Soldan et 
al,, 1997), more HHV-6 DNA in blood serum (Álvarez-Lafuente et al,, 2002, Tejada-
Simon et al,, 2002 and Tomsone et al,, 2001) and evidence of active HHV-6 infection 
more often (Chapenko et al,, 2003 and Álvarez-Lafuente et al,, 2002). None of these 
studies found these HHV-6 markers in all the subjects with MS and all the markers were 
found in some of the control subjects.  
Another study found higher levels of HHV-6 DNA from PwMS during relapses than 
those who were in remission (Berti et al, 2002), although another study was unable to 
detect a difference (Alvarez-Lafuente et al, 2002). A study of people with multiple 
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sclerosis in Kuwait failed to find evidence of HHV-6 DNA in the blood of a small sample 
of people with MS (Al-Shammari et al, 2003).  
Attempts to find active HHV-6 in cerebrospinal fluid (CSF) or other CNS tissue have 
been mixed. Some studies have been successful (Goodman et al, 2003, Cermelli et al, 
2003, Tejada-Simon et al,, 2002 and Knox et al, 2000) but others have failed to replicate 
these findings (Rodriguez Carnero et al,, 2002 and Gutiérrez et al, 2002). One way that 
HHV-6 might be involved is through a mechanism called molecular mimicry. It is 
proposed that a small section of one of the HHV-6 proteins resembles a small section of 
one of the proteins in myelin - the insulating substance around brain cells that is damaged 
in multiple sclerosis. This resemblance means that our immune systems are unable to 
differentiate between the two and mistakenly attack the myelin as well as the virus. One 
study has identified a candidate section in one myelin protein, called Myelin Basic 
Protein (MBP), and showed it to be activated by an HHV-6 protein in people with MS 
(Tejada-Simon et al, 2003). However, another laboratory failed to show any increased 
ability of HHV-6 to activate MBP-reactive T cells in PwMS (Cirone et al, 2002).  
It has also been suggested that protein produced by HHV-6 attracts certain immune 
system cells (macrophages and monocytes) (Luttichau et al, 2003). Perhaps it does this so 
that it can infect them but these researchers suggest that this function is also involved in 
the multiple sclerosis disease process.  
Another way HHV-6 might be involved in MS is via a cell surface protein, called 
membrane cofactor protein (CD46). This protein is responsible for regulating a branch of 
the immune system, called complement, and preventing complement activation on the 
bodies own cells. However, CD46 has also been identified as the cellular receptor for 
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HHV-6 (Santoro et al, 1999). Elevated levels of soluble CD46 have been found in both 
the blood and the cerebrospinal fluid of people with MS (Soldan et al, 2001). 
Association with malignancies 
HHV-6 DNA sequences have been identified in a number of human malignancies, 
including Hodgkin’s disease and non-Hodgkin’s lymphoma, as well as some cases of T-
cell acute lymphoblastic leukaemia and T-cell chronic lymphoproliferative disease 
(Pellett et al, 1995). In addition, whole HHV-6 DNA, or cloned fragments of the viral 
genome have been shown to be capable of oncogenically transforming cultured cells 
(Thomson et al, 1994, Razzaque et al, 1993). Despite these observations, the hypothesis 
that HHV-6 might have a direct or aetiologic role in human malignancy remains 
unproved, in large part because the virus might simply be a ‘passenger’ in most, or even 
all, of the tumor tissues in which it has been detected (Pellett et al, 1995). 
2.3.1.5 Association with disease in immunocompromized individuals  
Role in post-transplant disease  
Given the fact that HCMV is probably the most important viral pathogen in the post-
transplantation setting, it would seem likely that a closely related virus such as HHV-6 
might also lead to post-transplant complications. Several studies have demonstrated that 
this is indeed the case. 
HHV-6 has been linked, most frequently, to disease in bone marrow transplant (BMT) 
recipients, although complications in renal and liver transplant recipients have also been 
described (Pellett et al, 1995). In BMT recipients, HHV-6 was isolated from 
approximately 40% of individuals (6/16 cases examined) who developed idiopathic 
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febrile illness (fever of unknown origin) following bone marrow engraftment (Drobyski 
et al, 1993). The isolation of HHV-6 from PBMC was frequently associated with 
idiopathic bone-marrow suppression, and HHV-6 could also be isolated directly from the 
bone marrow of such individuals (Drobyski et al, 1993). These findings, together with the 
ability of HHV-6 to suppress the in vitro maturation of bone-marrow precursor cells, 
suggest that the virus might be a cause of bone-marrow suppression in BMT recipients.  
HHV-6 antigens and DNA have also been detected in the lung tissue from BMT 
patients with otherwise idiopathic pneumonitis (inflammation of the lung of unknown 
origin; Cone et al, 1993, Carrigan et al, 1991), although the overall frequency of HHV-6 
related pneumonias in recipients of BMT remains rather unclear, as does the overall 
importance of HHV-6 as a pathogen in the post-transplantation setting. 
Role in Chronic Fatigue Syndrome 
The notion that HHV-6 might play a role in the pathogenesis of Chronic Fatigue 
Syndrome has existed in the literature for many years. However, data concerning the 
relationship, if any, between CFIDS and HHV-6 are at best, conflicting. For example, 
there is an increase in the prevalence of IgM antibodies to HHV-6 in people with CFIDS 
(Patnaik et al, 1995), while several other groups have concluded that there is no evidence 
of any relationship between anti-HHV-6 antibody titres and CFIDS (Mawle et al, 1995, 
Buchwald et al, 1996, Levine et al, 1992). It, therefore, seems unlikely that HHV-6 is 
involved in the pathogenesis of CFIDS, although additional studies might be warranted 
(Pellett et al, 1995). 
 
 54
2.3.1.6 Relationship between HHV-6 and HIV-1 
The interplay between HHV-6 and HIV-1 has been studied extensively, at least in 
vitro. HHV-6 infection can induce de novo expression of CD4 on some cells of 
haematopoietic lineage (Lusso et al, 1991, Furlini et al, 1996), rendering such cells 
susceptible to infection by HIV-1 (Lusso et al, 1993). In addition, HHV-6 and HIV-1 can 
co-infect the same cells, and HHV-6 gene products can trans-activate the long terminal 
repeat (LTR) of HIV-1 (Pellett et al, 1995). However, in vivo studies of the role of HHV-
6 in disease progression in AIDS have yielded somewhat contradictory results, at least in 
adults.  
Several investigators have suggested that HHV-6 might enhance HIV-1 replication 
and broaden the in vivo host-cell range of HIV-1 (Knox et al, 1996, Lusso et al, 1995), 
but others have found no correlation between antibody titres to HHV-6, or numbers of 
copies of HHV-6 DNA in saliva, and progression of HIV-1 related disease (Spira et al, 
1990, Fairfax 1994). Nonetheless, it appears likely that HHV-6 might be reactivated in 
people infected with HIV-1 (Prezioso et al, 1992, Knox et al, 1994), and that the virus 
can, at least occasionally, cause serious disease in immunosuppressed individuals, 
including pneumonitis and encephalitis (see above). It might, therefore, be important to 
examine the role that HHV-6 plays in disease progression in HIV-1-infected infants, in 
whom primary HHV-6 infection might occur, resulting in HHV-6 viraemia and immune 




2.3.1.7 Clinical implications/applications 
Primary infection  
Acute childhood infection with HHV-6 is usually self-limiting, but can be associated 
with more severe complications, which have both medical and economic impact. In one 
large prospective study of viral complications and reactivation, approximately 13% of 
children with primary viral infection developed seizures and a similar number required 
hospitalization (Hall et al, 1994). By the age of one year, approximately 90% of children 
have detectable levels of antibody to HHV-6 (Carrigan D. R. and K. K. Knox, 2000). 
Furthermore, primary HHV-6B infection accounted for 20% of all emergency department 
visits for febrile illnesses in children 6–12 months old, in one large university hospital in 
North-Eastern USA (Cone et al, 1993). 
The strikingly high fevers (> 400C) and frequent neurological symptoms, which are 
associated with HHV-6 infection, often elicit time-consuming and expensive clinical 
laboratory tests to rule out more serious diseases, such as bacterial infections of the CNS. 
Moreover, the importance of making the correct diagnosis means the avoidance of 
uncessary and wrong usage of antibiotics. This suggests the need for rapid, sensitive and 
specific diagnostic tests for HHV-6, which could be applied in a clinical setting.  
An anti-HHV-6 vaccine might have medical and societal value; the frequency of 
HHV-6-related acute disease, the duration of illness, and the possibility for complications 
are, in extremely broad terms, similar in scope and magnitude to the corresponding 
parameters for varicella zoster virus (VZV), which is the causative agent of chicken pox 
and shingles. Cost–benefit analyses and medical considerations have provided a 
compelling rationale for routine vaccination of children in the world against VZV, and 
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similar analyses of the potential benefits of immunisation for HHV-6 might, therefore, be 
necessary.  
Management of severe complications of infection, including neurological disease 
The association of HHV-6 with severe complications such as encephalitis or 
pneumonitis, particularly in immunocompromised individuals, suggests the need to 
identify effective antiviral drugs. In vitro studies have shown that HHV-6 is relatively 
resistant to acyclovir, which is consistent with the fact that the virus does not encode a 
thymidine kinase. In contrast, the virus is sensitive to ganciclovir and phosphonoformic 
acid (foscarnet). In vivo evaluation of antiviral strategies for HHV-6 has not, however, 
been reported, and it is also uncertain whether the novel inhibitors of HSV-1 










CHAPTER 3: MATERIALS AND METHODS
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3.1 Enterovirus 71 
3.1.1 Bacteria and Yeast transformation 
The viral coat protein 1 of the neurovirulent strain EV71/7423/MS/87, courtesy of D. 
M. A. Pallansch, CDC, Atlanta, GA, USA, was used as a bait in the the Yeast Two-
Hybrid screening. Two pretransformed MATCHMAKER cDNA libraries from ClonTech, 
brain and bone marrow, were used in this screening. All procedures described below 
were carried out using aseptic techniques or in the Class 2A Biosafety cabinet. 
The viral coat protein 1 of the neurovirulent strain EV71/7423/MS/87 was amplified 
with Pfu (Promega) using the primer pairs VP1F and VP1R (Table 5). Additional 
nucleotides were included at the 5’ ends of both primers to increase the efficiency of the 
restriction endonuclease reaction of the PCR product. Pfu from Promega was used for the 
PCR to ensure high fidelity of the product. The product was then subjected to gel 
electrophoresis and purified by QIAquick gel purification kit (QIAGEN). The primers 
were engineered with a SfiI and a SalI site in the VP1F and VP1R primers, respectively. 
The pGBKT7 (ClonTech) vector and the purified PCR product were subjected to a 
double digestion reaction with SfiI and SalI endonucleases. The digested products were 
purified and ligated using T4 DNA ligase at 40C overnight. 
The construct was transformed into XL1-Blue E. coli cells via electroporation and 
plated onto selective media (LB + ampicillin) (appendix) overnight. The efficiency of the 
electroporation is 40%. Colony PCRs were conducted on the colonies obtained to isolate 
the bacteria carrying the plasmid constructs. The clones were then amplified overnight 
and their plasmid constructs harvested usng the QIAprep Spin Miniprep Kit (QIAGEN). 
Each plasmid construct was subjected to automated cycle sequencing using the BD-
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vector primer (FORBID, Table 4) and VP1-specific primers to confirm mutation-free, in-
frame insert. 
Each construct (bait) was then transformed into commercially available PJ69-2A dual 
reporter yeast strain (Trp-) via a lithium acetate-mediated small scale yeast transformation 
procedure (Yeast Protocol Handbook PT3024-1, ClonTech). The efficiency of the 
transformation was improved by using a 0.1µg plasmid DNA to 0.1mg Salmon sperm 
carrier DNA (Gibco) ratio. To the above mixture, 0.6ml of fresh, sterile PEG/LiAc 
solution (Appendix) was added and the solution vortexed at high speed for 10 seconds. 
The mixture was then incubated at 300C for half an hour with shaking at 200 rpm. 70µl of 
sterile DMSO (Sigma-aldrich) was added and mixed into the solution by gently inverting 
the tube. Heat treatment using water bath was carried out at 420C for 15 mins. The cells 
were then subjected to 40C treatment for 2 mins followed by pulsed centrifugation. They 
were then reconstituted with 1 x TE (Appendix) and 100µl each were plated onto 
synthetic dropout agar plates lacking trytophane (SD/ -Trp). Only successful 
transformants will be able to grow on this selective agar plate. Successful transformants 
were also plated onto synthetic dropout agar plates lacking trytophane and histidine (SD/ 
-Trp/ -His).  This is necessary to ensure there is no autonomous activation of the His 
reporter gene by the bait fusion protein alone.  
3.1.2 in vivo protein expression 
Total protein was extracted from the transformed PJ69-2A yeast cells and western 
blot analysis was carried out. An overnight yeast culture with OD600 = 2.0 units was 
transferred to a 13mm tube containing ice cold 2 ml of 50mM Tris (pH7.5) and ice cold 
10mM Na N3 , and centrifuged to pellet the cells. The pellet was re-suspended with 30µl 
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of ESB solution (Appendix), transferred to a microfuge tube and heated to 1000C for 3 
mins to inactivate any proteases activities. To the heated pellet, 0.1g of 0.2mm acid- 
washed glass beads was added and the mixture was subjected to vigorous vortexing for 2 
mins to assist in the breaking up of the yeast cells. The beads were removed by pulsed 
centrifugation and the cell lysate was subjected to 1000C for 3 mins before loading into a 
SDS-PAGE gel. Immunoblot experiment was carried out as described in Section 3.1.5. 
3.1.3 Yeast two-hybrid techniques 
Yeast Two-Hybrid screening involving both the pretransformed human brain 
(ClonTech HY4004AH) and bone marrow (ClonTech HY4053AH) cDNA libraries were 
carried out with the VP1 plasmid construct. Successfully transformed clones (described 
in Section 3.1.1) were cultured overnight at 300C with shaking at 250 rpm in 50 ml of 
SD/ -Trp broth. At approximately OD600 = 0.8-0.9, the culture was subjected to 
centrifugation at 3000 rpm, washed 1 times with YPD (Appendix) and re-suspended with 
50ml YPDA/Kan (Appendix) in a 2-L Erlenmeyer flat-bottomed flask. 100µl of each 
pretransformed cDNA library was added to each 50 ml YPDA/Kan culture and incubated 
for 20-24 hrs at 300C with shaking at 50rpm. A sample of the mating culture was 
obtained to ensure that mating (diploid cell formation) has concluded before proceeding 
further. The entire culture was then subjected to 10 mins of 3000 rpm centrifugation and 
re-suspended in 10 ml YPDA/Kan. The entire 10 ml cell suspension was plated onto SD 
agar plates lacking Leucine, Trytophane, Histidine and Adenine (SD/ -Leu/ -Trp/ -His/ -
Ade) with 150µl into each plate. The plates were inverted and incubated at 300C for 8-21 
days with frequent observations. The colonies that grew were re-streaked onto the same 
dropout agar and assayed for LacZ phenotype via presence of β-galactosidase activity 
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(which is a good indication of the strength of protein-protein interactions) and presence 
of the BD and AD plasmid constructs via colony PCR. 
Yeast was permeabilized by freezing yeast-impregnated filters in liquid nitrogen, 
and thawing at room temperature. This filter was placed over a second filter that was pre-
soaked in a 0.1 M phosphate buffer (pH 7.0) containing 300 mg/ml 5-bromo-4-chloro-3-
indolyl-β-D-galactopyranoside (CPRG) and 0.27% β-mercaptoethanol. Filters were left 
for 8 hrs to develop a blue color, which indicated a positive protein-protein interaction. A 
mating control cross supplied with the library was performed concurrently, and also used 
as a positive control for the LacZ colony-lift assay as well as an indication of the mating 
efficiency. 
Activation domain (AD) vector primers, FAD and RADO (Table 4) were designed to 
amplify AD vector-inserts. LacZ(+) colonies were screened via direct colony PCR by 
resuspending the diploid yeast cells in 5 µl of 0.02 M NaOH on ice. PCR with vectors 
primers, FORBID, FAD and RADO (Table 4) was then performed using Advantage 2 
DNA polymerase mix (Clontech). Only clones showing positive for β-galactosidase 
activity and positive for two PCR products were accepted as true positives. Amplified 
fragments from positive clones were purified and subjected to cycle sequencing. 
BLASTN and BLASTP algorithms were used to analyze the resultant sequence data from 
the clones. 
3.1.4 Culturing of Mammalian cells 
Vero (African Green Monkey Kidney) cells (from A/P Mary Ng’s laboratory) were 
cultured in 6-well Tissue Culture plates using 2 ml of DMEM 10 (Appendix) per well. 
The cells were about 70% confluent after 24 hrs of growth at 370C in the CO2 incubator. 
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3.1.5 in vivo transcription/translation assay  
Expression vectors pCMV-HA and pCMV-c-Myc (ClonTech) were used as 
expression vectors as the majority of the restriction endonuclease sites were identical to 
the BD and AD vectors. VP1 was cloned into pCMV-HA vector using SfiI and SalI. ODC, 
GTAR and KIAA0697 were cloned into pCMV-c-Myc using SfiI/SalI and SfiI/Sal and 
EcoRI/SalI, respectively. They were then transformed into DH5α E. coli as described in 
Section 3.1.1. The constructs were then amplified, harvested and sequenced as described 
in Section 3.1.1. 
The integrity of the constructs was tested using the TNT T7 Quick Coupled 
Transcription/Translation System (Promega) for eukaryotic in vitro translation. The 
reaction mix consisting of each plasmid DNA, TNT Quick master mix, [35S]methionine 
and amino acid mixture (minus methionine) was incubated at 30°C for 90 min. T7 
luciferase DNA served as the positive control, while the negative control reaction 
contained no added DNA to measure any background incorporation of labeled amino 
acids. The translated peptides were concurrently resolved with Rainbow [14C] methylated 
protein markers (Amersham Pharmacia) using SDS-PAGE, followed by autoradiography. 
 
3.1.6 Cellular transfection and translation assays 
An expression vector (pCMV-HA) incorporating the 891-bp VP1 sequence of the 
EV71/7423/MS/87 strain was transfected into Vero African green monkey kidney cells 
using Transfectin reagent (Bio-Rad, Hercules, CA, USA). Similarly, expression vectors 
(pCMV-Myc) incorporating the partial coding sequences of ODC1 (380 bp), GTAR (904 
bp) or KIAA0697 (571 bp) were transfected into Vero cells. The integrity of each 
recombinant expression plasmid was tested by single transfection of each individual 
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construct in VERO cells, and each total cell lysate immunoblotted with the respective 
antibody of interest. Individual and/or dual transfections (e.g. pCMV-HA-VP1 with 
pCMV-Myc-ODC1) were then performed. A minimum transfection efficiency of 50% 
was achieved before proceeding with harvesting of proteins. Expression of the fusion 
proteins (i.e. HA-VP1, Myc-ODC1, Myc-GTAR or Myc-KIAA0697) was allowed to 
occur for 48 h. Total protein was harvested using lysis buffer (1% Triton X-100 and PBS, 
pH 7.4), and the cell lysate was centrifuged at 12,000 rpm for 10 min. The supernatant 
was then pretreated with sepharose A and A/G beads (Calbiochem, San Diego, CA, USA) 
at 40C for 1 h. The supernatant sepharose beads mixture was then centrifuged at 12,000 
rpm at 40C for 10 min. The supernatant was then incubated with sepharose A and A/G 
beads, pretreated with anti-HA antibody at 40C for 4 h. The mixture was then centrifuged 
at 5000 rpm for 10 s. The supernatant was discarded, and the beads were washed three 
times with PBS. The beads were then resuspended with 2_SDS sample loading buffer, 
heated at 990C for 3 min, and subjected to SDS-PAGE (10%). Western blot analysis was 
then carried out using antibodies against the HA or Myc epitopes. Lysates from cells 
transfected with the empty vector expressing either the HA or Myc tags were included as 
negative controls. 
 
3.1.7 Confocal immunofluorescence staining Assay 
Vero cells were grown on methanol-treated coverslips in 6-well cell culture plates 
overnight. Cells that were 60–80% confluent were then transfected as above using the 
VP1 and/or ODC1 plasmid constructs, and incubated at 370C for 48 h. Similar 
experiments were set up for the VP1 and GTAR constructs, as well as the VP1 and 
KIAA0697 constructs. The transfected cells were then washed twice with cold PBS, and 
incubated at -200C with cold methanol for 4 min. They were then incubated at room 
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temperature for 3 min before being washed thrice with cold PBS. Each primary or 
secondary antibody was reconstituted with FDB (Appendix), centrifuged at 12,000 rpm at 
40C for 10 min in the dark, and the supernatant used. The coverslips were incubated at 
room temperature for 1 h with primary anti-c-Myc monoclonal or anti-HA polyclonal 
antibody. They were then washed 5 times with cold PBS before being incubated at room 
temperature for 1 h with secondary FITC-tagged anti-mouse or rhodamine phalloidin-
tagged anti-rabbit antibody. The coverslips were then washed six times with cold PBS, 
mounted onto glass slides using mounting media (Vectashield, DAKO), and examined by 
XYZ-scanning confocal microscopy.  
 
3.1.8 EV71 infection of VERO cells 
VERO cells (90% confluent) were infected with live EV71/7423/MS/87 strain at a 
multiplicity of infection (MOI) of ~2 for 1 and 4 h. The cells were treated as described 
above, incubated with mouse anti-VP1 monoclonal antibody (Chemicon, Temecula, CA, 
USA), and counter-labeled with FITC-tagged anti-mouse antibody. The infected cells 
were also separately incubated with mouse anti-VP1 monoclonal antibody and goat anti-
ODC1 polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and 
counter-labeled with rhodamine phalloidintagged anti-mouse antibody and FITC-tagged 
anti-goat antibody, respectively. 
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3.2 Human Herpesvirus Type 6 
3.2.1 Bacteria and Yeast transformation 
The full-length U95 gene of HHV-6B strain HST (GenBank accession no. 
AB_021506: nucleotides 144230-147868), courtesy of Yuji Isegawa, Department of 
Microbiology and Division of Advanced Medical Bacteriology, Osaka University 
Medical School, Japan, served as the bait and was cloned into the pGBKT7 yeast two-
hybrid vector resulting in an N-terminal in-frame fusion with the GAL4 DNA-binding 
domain (BD). The insert was sequenced before being transformed into the 
Saccharomyces cerevisiae host reporter strain PJ69-2A. The bone marrow 
pretransformed MATCHMAKER cDNA library from ClonTech was used in this 
screening. All procedures described below were carried out using aseptic techniques or in 
the Class 2A Biosafety cabinet. 
The U95 of HHV6 was amplified with Pfu (Promega) using the primer pairs U95F-
SfiI and U95R-PstI (Table 4). The primers were engineered with a SfiI and a PstI site in 
the U95F-SfiI and U95R-PstI primers, respectively. The pGBKT7 vector and the purified 
PCR product (purification procedure as described in Section 3.1.1) were subjected to a 
double digestion reaction with SfiI and PstI endonucleases. The digested products were 
purified and ligated using T4 DNA ligase at 40C overnight  
The construct was transformed into DH5α E. coli cells and subsequently into yeast as 




3.2.2 in vivo protein expression 
Total protein was extracted from the transformed PJ69-2A yeast cells as described in 
section 3.1.2. 
3.2.3 Yeast Mating experiment 
The experiments were performed using the yeast two-hybrid system 2 kit as described 
in section 3.1.3.  
 
3.2.4 Propagation of the human MT-4 cell line, transfection and co-
immunoprecipitation assays. 
MT-4 cells were cultured in 25 cm2 cell culture flasks each with 5 ml of RPMI 1640 
medium supplemented with 10% fetal bovine serum at 37°C with 5% CO2. Expression 
vectors pCMV-HA and pCMV-Myc (Clontech) were used as most of their restriction 
endonuclease sites were identical to the BD and AD vectors. The U95 fragment was 
amplified with PCR primers U95F-SfiI and U95R-NotI (Table 5), and cloned into the 
pCMV-HA vector at the SfiI and NotI sites. The full-length coding sequence of GRIM-19 
(GenBank accession no. NM_015965: nucleotides 260-943) was cloned into pCMV-Myc 
at the SfiI and SalI sites. Both clones were transformed into E. coli strain DH5α, purified 
using plasmid spin columns (Qiagen, Hilden, Germany), and then transfected, 
individually or together, into MT-4 cells using Transfectin reagent (Bio-Rad, Hercules, 
CA). Empty vectors transfected into MT-4 cells served as negative controls. Expression 
of the fusion proteins was allowed to occur for 48 h. Total protein was harvested using 
lysis buffer (1% Triton X-100 and PBS, pH 7.4), and the cell lysate was centrifuged at 
12,000 rpm for 10 min. The supernatant was pretreated with sepharose A and A/G beads 
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(Calbiochem, San Diego, CA) at 4°C for 1 h, and the mixture centrifuged at 5,000 rpm 
for 5 min to remove the beads. The supernatant was incubated with sepharose A and A/G 
beads which were pretreated with anti-HA and/or anti-Myc antibodies at 4°C for 4 h. The 
mixture was centrifuged at 5,000 rpm for 10 sec, the supernatant was discarded, and the 
beads were washed thrice with PBS. The beads were resuspended with 2× SDS sample 
loading buffer, heated at 99°C for 3 min, and the proteins subjected to SDS-PAGE (10%). 
Western blot analyses were then carried out using antibodies against the HA or Myc 
epitopes. Negative controls included mixed lysates from cells transfected with the 
plasmids expressing either the HA or Myc tags only (Sim et al, 2002 and Yeo W. M. and 
V. T. Chow, 2007) 
 
3.2.5 Immunofluorescence confocal microscopy. 
MT-4 cells (106 in each 25 cm2 cell culture flask) were grown overnight, and then 
transfected as above using the expression plasmid constructs. The cells were incubated at 
37°C for 24 h, and transfection was repeated at 48 h. The transfected cells were then 
washed thrice with PBS, and immobilized onto glass slides using a cytospin. The 
immobilized cells were washed twice with cold PBS, and incubated with cold methanol 
at -20°C for 4 min. They were incubated at room temperature for 3 min before being 
washed thrice with cold PBS. The slides were incubated at room temperature for 1 h with 
primary anti-Myc monoclonal and/or anti-HA polyclonal antibody. They were then 
washed five times with cold PBS before being incubated at room temperature for 1 h with 
secondary FITC-tagged goat anti-mouse or rhodamine phallioidin-tagged goat anti-rabbit 
antibody. The glass slides were washed six times with cold PBS before being mounted on 
coverslips using Vectashield mounting media (Dako, Glostrup, Denmark), and examined 
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by confocal microscopy (38, 45). Mitochondria were labeled with MitoTracker Green 
FM (Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol. 
 
3.2.6 Determination of virus titer by TCID50 and assay for cell viability. 
MT-4 cells (105 per well) were propagated in cell culture plates overnight and then 
infected with HHV-6B strain HST, achieving cytopathic effect (CPE) in 50% of the cells 
after 48 h. The tissue culture infectious dose (TCID50) was derived from the observation 
of CPE, i.e. the induction of syncytial formation in 50% of the cell population (19). An 
infecting dose of 105 TCID50 of HHV6-B virus was selected. After infection for 48 h, cell 
viability was determined by staining with 0.4% trypan blue, and counting the cells using 
a hemocytometer under light microscopy. Viable cells were observed as unstained, 
translucent bodies while dead cells were stained blue. No significant cell death or debris 
was observed for 5 days post-infection, with HHV-6B-infected cells appearing as 
unstained, large cells with syncytial formation. 
 
3.2.7 Short hairpin RNA (shRNA) constructs to induce specific antiviral response by 
RNA interference (RNAi). 
The GenBank database was searched for unique sequences within U95 and to exclude 
homology to known human and other viral genes. Using siRNA software (Ambion, 
Austin, TX), a 19-mer region of the HHV-6B U95 gene (GenBank accession no. 
AB_021506: nucleotides 144460-144478) was selected as the target for RNAi. The U95-
specific shRNA duplex oligonucleotides were designed and chemically synthesized 
(Sigma-Proligo, Boulder, CO), consisting of an antisense strand (5′-AGUCGACAGUGA 
UUCGCGGUU-3′), and a sense strand (5′-CCGCGAAUCACUGUCGACUUU-3′). 
Scrambled shRNA was designed by random arrangement of the same number of A, C, G 
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and U nucleotides in the U95 shRNA construct, and confirmed to lack homology to viral 
and human genes in GenBank. The scrambled sequence shRNA duplex was synthesized 
(antisense 5′-GGGUGACACGUAGUCAGCUUU-3′  and sense 5′-AGCUGACUACGU 
GUCACCCUU-3′) to serve as the negative control for all the RNAi experiments (Tan et 
al, 2007). 
 
3.2.8 Real-time RT-PCR. 
Total mRNA samples from uninfected, HHV6B-infected, HHV6B-infected but U95-
shRNA-treated, as well as HHV6B-infected but scrambled-shRNA-treated cells were 
isolated using a total mRNA isolation kit (Qiagen). Genomic DNA contamination was 
minimized by treating the samples with DNase provided in the kit. Each purified total 
mRNA was then subjected to RT-PCR using Superscript II reverse transcriptase 
(Invitrogen) and 100 µM of random hexamers (Promega, Madison, WI) at 42°C for 1 h. 
The reaction was terminated by incubating the mixture at 95°C for 10 min. The cDNA 
concentrations were standardized to 120 ng/µl. Real-time RT-PCR analyses were 
performed in triplicate with a LightCycler (Roche, Mannheim, Germany) using SyBR-
Green with primers flanking a 317-bp fragment (GenBank accession no. AB_021506: 
nucleotides 145165-145481) within the U95 gene (5′-GGCGACACAACTAAGCGCAT 
C-3′ and 5′-CGGAAATGGCCGCATCTACAC-3′), and with primers for the 
glyceraldehyde-3-phosphate dehydrogenase (G3PDH) housekeeping gene which served 
as a normalization reference (5′-AGGTGAAGGTCGGAGTCAAC-3′ and 5′-
CATGGGTGGAATCATATTGG-3′). Each 10 µl RT-PCR mix included 1 µl of cDNA, 
0.5 µM of each primer, 2.5–3 mM MgCl2, and 1 µl of 10× Hot Start reaction mix (Roche). 
The reactions were subjected to an initial denaturation of 95°C for 10 min, followed by 
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35 cycles each of 95°C for 10 sec, 65°C for 5 sec and 72°C for 10 sec, before subjecting 
to melting curve analysis of 1 cycle with 15 sec hold at 65°C. Real-time RT-PCR of each 
sample using the two primer sets was conducted in triplicate to ensure consistency in 
threshold cycle (CT) values. The mean CT values were used for calculating the relative 
expression levels as described previously (Leong, W. F. and V. T. Chow. 2006). The 
normalized CT values for the U95 gene were subjected to Student’s t-test with two-tailed 
distribution to determine the significance at the 95% confidence level.  
 
3.2.9 Transmission electron microscopy. 
MT-4 cells were propagated for 24 h, and were infected with HHV-6B as described 
above. Uninfected MT-4 cells were included as negative controls. At 0, 1, 4 and 7 h post-
infection, both infected and uninfected cells were fixed with 2.5% glutaraldehyde in 0.1 
M phosphate buffer (pH 7.4) at room temperature for 1 h. The fixed samples were then 
post-fixed with 2% osmium tetroxide at room temperature for 1 h, dehydrated in a graded 
alcohol series, and embedded in Epon812. Ultrathin sections (20 nm thick) were cut with 
a microtome, stained with uranyl acetate and lead citrate for 20 and 10 min, respectively, 
and observed using a Philip model 208S electron microscope (Lim et al, 2004). 
 
3.2.10 Mitochondrial membrane potential assay by flow cytometry. 
One h post-infection, the HHV-6-infected cells were transfected with either U95-
shRNA or scrambled-shRNA (85 nM each) using Lipofectamine 2000. They were then 
washed once with PBS, and incubated with MitoProbe DiOC2(3) dye (Invitrogen). Two 
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4.1 EV71 
Yeast two-hybrid analyses with brain and bone marrow cDNA libraries 
From the yeast mating experiments, 22 out of 63 clones from the brain cDNA library 
and 49 out of 107 clones from the bone marrow library were positive by both colony PCR 
screening (Fig. 4.1.1) and β-galactosidase assay. Three clones were stringently selected 
based on the criteria of showing the strongest β-galactosidase activity compared with the 
positive control (Fig. 4.1.2), and of being the most frequently appearing positive clones, 
i.e. ODC1 (1 in 4) and KIAA0697 (1 in 3) from the brain library, and GTAR (1 in 3) 
from the bone marrow library. As the libraries were generated from random cDNA 
fragments, all three selected clones were not full-length coding sequences, i.e. ODC1 
(with the largest fragment spanning nucleotides 1310–2015, GenBank No. NM_002539), 
KIAA0697 (with the largest fragment spanning nucleotides 282–1325, GenBank No. 
AB014597.2), and GTAR encoded by ankyrin repeat domain 17 (ANKRD17) transcript 
variant 1 (with the largest fragment spanning nucleotides 5818–9070, GenBank No. 
NM_032217). 
 
In vitro and cellular expression studies 
Using a coupled in vitro transcription–translation reticulocyte lysate system 
(Promega, Madison, WI, USA) and 35S-labeling of proteins, protein expression was 
carried out to verify the integrity of the above constructs and to ensure a transfection 
efficiency of at least 50% before proceeding with the cellular expression experiments. In 
cells co-transfected with pCMV-HA-VP1 together with either pCMV-Myc-ODC1, 
pCMV-Myc-GTAR or pCMV-Myc-KIAA0697 constructs, Myc-ODC1, Myc-GTAR or 
Myc-KIAA0697 proteins could be respectively co-immunoprecipitated using 
immobilized anti-HA-VP1 antibody-protein complex as indicated by the Western blot 
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results (Fig. 4.1.3-4.1.5). The total lysate from cells co-transfected with pCMV-Myc and 
pCMV-HA constructs served as the negative control for the above experiments. These 
results confirmed the interactions between the VP1 protein and ODC1, GTAR, 
KIAA0697 proteins in mammalian cells. 
 
Indirect immunofluorescent microscopy 
Immunofluorescent microscopy experiments provide evidence that the VP1 protein 
of EV71 co-localized with ODC1, GTAR and KIAA0697. As these are generally 
cytoplasmic proteins, three-dimensional confocal immunofluorescence microscopy or Z-
stack scan was included for all sets of experiments to ensure that the observed co-
localization was not merely coincidental overlapping images or leaky signals. Strong 
cytoplasmic with perinuclear co-localization was observed for VP1 and ODC1 (Fig. 
4.1.6). The association between VP1 and GTAR was also detected in the nucleus (Fig. 
4.1.7). Predominant perinuclear co-localization was observed between VP1 and 
KIAA0697 (Fig. 4.1.8). Fig. 4.1.9 shows indirect immunofluorescent staining of Vero 
cells following infection with live EV71 for 4 h and Fig. 4.2.10 shows highly significant 
co-localization of native VP1 with endogenous ODC1 that increased substantially from 1 
to 4 h post-infection. Negative controls using only empty pCMV-Myc and pCMV-HA 
plasmids were also included (Fig. 4.1.11). Z-stack scans at a minimum of 64 slices and 
0.2 mm depth intervals were performed. On the average, 85% of the slices showed both 















Fig. 4.1.1. Colony PCR screening of yeast two-hybrid colonies. Gel electrophoresis 
of PCR products of 14 selected colonies from the QDO plates. Each positive clone 
must contain both the bait fragment within the BD vector (odd-numbered lanes) and 
a random fragment within the AD vector from the cDNA library (even-numbered 
lanes). Positive clones harboring both VP1 and ODC1 fragments (lanes 1–4, 13–16), 
as well as both VP1 and GTAR fragments (lanes 5–6, 17–20, 25–28) are illustrated. 
Lane M depicts DNA markers 
Weak 
Strong 
Fig. 4.1.2. β-galactosidase assay for 
yeast two-hybrid analysis showing 
both positive and negative results. A 
strong positive representing the 
ODC1 clone is circled.   
M   1     2   3    4    5   6    7   8    9  10   11 12  13 14  15  16  17 18 19  20 21 22  23 24  25 26  27  28 
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   M  1  2       3   4 
42-kDa VP1
23-kDa ODC1
Fig. 4.1.3. Co-immunoprecipitation of EV71 VP1 (40 kDa) and human ornithine 
decarboxylase (23 kDa). BenchMark protein ladder (Invitrogen, Carlsbad, CA, USA) 
(Lane M). Cells were co-transfected with pCMV-Myc and pCMV-HA vectors, and 
the lysate was immunoblotted with monoclonal antibodies against Myc and HA tags 
(Lane 1). Cells were co-transfected with pCMV-Myc-ODC1 and pCMV-HA-VP1 
constructs, the lysate incubated with anti-HA antibody immobilized onto protein A/G 
beads, and the mixture immunoblotted with antibodies against Myc and HA (Lane 2). 
This experiment was repeated using immobilized anti-Myc instead of anti-HA 
antibody (data not shown). Cells were transfected with pCMV-Myc-ODC1 construct, 
the lysate incubated with anti-Myc monoclonal antibody immobilized onto protein 
A/G beads, and the mixture immunoblotted with anti-Myc (Lane 3). Cells were 
transfected with pCMV-HA-VP1 construct, the lysate incubated with anti-HA 
monoclonal antibody immobilized onto protein A/G beads, and the mixture 
immunoblotted with anti-HA (Lane 4). The presence of bands of ~30 kDa region is 
likely due to the light chain of the immobilized primary antibody used.  
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M       1    2       3  4
40-kDa VP1 
65-kDa GTAR 
Fig. 4.1.4. Co-immunoprecipitation of EV71 VP1 (40 kDa) and human GTAR 
(65 kDa). BenchMark protein ladder (Invitrogen, Carlsbad, CA, USA) (Lane M). 
Cells were transfected with pCMV-Myc-GTAR construct, the lysate incubated with 
anti-Myc immobilized onto protein A/G beads, and the mixture immunoblotted with 
anti-Myc (Lane 1). Cells were transfected with pCMV-HA-VP1, the lysate 
incubated with anti-HA immobilized onto protein A/G beads, and the mixture 
immunoblotted with anti-HA (Lane 2). Cells were co-transfected with pCMV-Myc 
and pCMV-HA, and the lysate was immunoblotted with antibodies against Myc and 
HA (Lane 3). Cells were co-transfected with pCMV-Myc-GTAR and pCMV-
HAVP1 constructs, the lysate incubated with anti-HA immobilized onto protein A/G 
beads, and the mixture immunoblotted with antibodies against Myc and HA (Lane 
4). This experiment was repeated using immobilized anti-Myc instead of anti-HA 
(data not shown). The presence of a band of ~50 kDa is likely due to the heavy chain 








Fig. 4.1.5. Co-immunoprecipitation of EV71 VP1 (40 kDa) and human KIAA0697 (48 
kDa). BenchMark protein ladder (Invitrogen, Carlsbad, CA, USA) (Lane M). Cells were 
transfected with pCMV-Myc-KIAA0697 construct, the lysate incubated with anti-Myc 
immobilized onto protein A/G beads, and the mixture immunoblotted with anti-Myc (Lane 1). 
Cells were transfected with pCMV-HA-VP1, the lysate incubated with anti-HA immobilized 
onto protein A/G beads, and the mixture immunoblotted with anti-HA (Lane 2). Cells were 
co-transfected with pCMV-Myc-KIAA0697 and pCMV-HA-VP1 constructs, the lysate 
incubated with anti-HA immobilized onto protein A/G beads, and the mixture immunoblotted 
with antibodies against Myc and HA (Lane 3). This experiment was repeated using 
immobilized anti-Myc instead of anti-HA (data not shown). Cells were co-transfected with 
pCMV-Myc and pCMV-HA, and the lysate was immunoblotted with antibodies against Myc 
and HA (Lane 4). 





Fig. 4.1.6. Co-localization of EV71 VP1 with ODC1. Vero cells were co-transfected with 
pCMV-Myc-ODC1 and pCMV-HA-VP1 constructs, fixed, immunolabeled and examined 
by immunofluorescent microscopy: (a) detection of Myc-ODC1 by mouse anti-Myc 
antibody, (b) detection of HA-VP1 by rabbit anti-HA antibody. The secondary antibodies 
were FITC-tagged anti-mouse antibody and rhodamine phalloidin-tagged anti-rabbit 
antibody, respectively, and (c) superimposed images of panels a and b showing co-
localization. 











Fig. 4.1.7. Co-localization of EV71 VP1 with GTAR. Vero cells were co-transfected with 
pCMV-Myc-GTAR and pCMV-HA-VP1 constructs, immunolabeled and examined by 
immunofluorescent microscopy: (a) detection of Myc-GTAR by mouse anti-Myc antibody, 
(b) detection of HA-VP1 by rabbit anti-HA antibody. The secondary antibodies were FITC-
tagged anti-mouse antibody and rhodamine phalloidin-tagged anti-rabbit antibody, 
respectively, and (c) superimposed images of panels a and b showing co-localization. 
enlarged images of individually stained nuclei, and (f) superimposed images of panels d and e 
showing co-localization. 
D E F 





Fig. 4.1.8. Co-localization of EV71 VP1 with KIAA0697. Vero cells were co-transfected 
with pCMV-Myc-KIAA0697 and pCMV-HA-VP1 constructs, immunolabeled and examined 
by immunofluorescent microscopy: (a) detection of c-Myc-KIAA0697 by mouse anti-Myc 
antibody and (b) detection of HA-VP1 by rabbit anti-HA antibody. The secondary antibodies 
were FITC-tagged anti-mouse antibody and rhodamine phalloidin-tagged anti-rabbit antibody, 
respectively, and (c) superimposed images of panels a and b showing co-localization. 
 CA B 
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Fig. 4.1.9. Specific detection of wild-type VP1 protein in EV71-infected cells. Vero 
cells were infected with EV71 at a MOI of ~2, fixed after 4 h, immunolabeled and 
examined by immunofluorescent microscopy: (a) the cells were incubated with mouse 
anti-VP1 monoclonal antibody, followed by FITC-tagged anti-mouse antibody, (b) 
cell nuclei were also stained blue with DAPI, and (c) higher magnification 
exemplifying the strong intensity of native VP1 localization. 
A B C 
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Fig. 4.1.10. Kinetics of co-localization of wild-type VP1 protein with endogenous 
ODC1 in EV71-infected cells. Vero cells were infected with EV71 at a MOI of ~2 for 1 
h (A-C) and for 4 h (D-F), fixed, immunolabeled and examined by immunofluorescent 
microscopy. (A, D) Detection of endogenous cellular ODC1 by goat anti-ODC1 antibody. 
(B, E) Detection of EV71 VP1 by mouse anti-VP1 monoclonal antibody. Secondary 
antibodies were FITC-tagged anti-goat antibody and rhodamine phalloidin-tagged anti-
mouse antibody, respectively. (C, F) Co-localization displayed by superimposed images 
of panels A/B and D/E respectively. 
A B C 
D E F 
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A B C 
Fig. 4.1.11. Negative controls for immunofluorescence studies. Vero cells were co-
transfected with empty pCMV-Myc and pCMV-HA vectors, fixed, immunolabeled and 
examined by immunofluorescent microscopy. (A) Reaction with mouse anti-Myc 
antibody. (B) Reaction with rabbit anti-HA antibody. The secondary antibodies were 
FITC-tagged anti-mouse antibody and rhodamine phalloidin-tagged anti-rabbit 
antibody, respectively. (C) Superimposed images of panels A and B. 
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      From the many positive clones identified by yeast two-hybrid mating experiments 
using pretransformed brain and bone marrow cDNA libraries, we selected three clones 
that exhibited strong β-galatosidase activity and high frequency of positivity. Colony 
PCR, co-immunoprecipitation, indirect immunofluorescence and confocal microscopy 
(Z-stack scan) were conducted to verify these interactions. We have thus authenticated 
the interaction of the VP1 capsid protein of EV71 with human ODC1, GTAR and 
KIAA0697 proteins in separate independent experiments. ODC1 is the first and rate-
limiting enzyme in polyamine biosynthesis. Polyamines play an essential role in the 
proliferation, growth, differentiation, apoptosis, and malignant development of 
mammalian cells (Pegg et al, 1986; Auvinen et al, 1992; Clifford et al, 1995; Shipper et 
al, 2002), and its depletion inhibits growth of neoplastic cells in vitro and in animal 
models (Shipper et al, 2004). The ODC1 and VP1 interacting proteins displayed a 
cytoplasmic, mainly perinuclear localization. In various cell types, ODC1 shows different 
localization patterns varying from exclusively cytoplasmic to both cytoplasmic and 
nuclear (Shipper et al, 2002), depending on the physiological status of the cells (Shipper 
et al, 2004; Tang et al, 2004). Thus, ODC1 is located in the perinuclear region during the 
G1 phase of the cell cycle (Shipper et al, 2004). Cellular polyamines are absolutely 
essential for cell proliferation in the crypts of small intestinal mucosa (Pegg et al, 1986), 
and for protein biosynthesis. Macrophage activation is accompanied by a rapid, transient 
upregulation of ODC1 mRNA level (Carnazzo et al, 1994). Macrophages activated with 
lipopolysaccharide, interferon-γ or tumor necrosis factor show a marked fall in secretion 
of reactive oxygen intermediates and cytotoxic activity when specific polyamine 
synthesis inhibitors are added (Carnazzo et al, 1994). We have demonstrated the kinetics 
of the intimate association between EV71 VP1 and endogenous ODC1, as evidenced by 
their similar cytoplasmic to perinuclear staining (Fig. 4.1.10). During EV71 infection, the 
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strong interaction between VP1 and ODC1 may compromise the latter’s activity, and 
adversely affect polyamine biosynthesis, growth and proliferation of infected cells (Tang 
et al, 2004). It is also noteworthy that via gene microarray, real-time RT-PCR and 
Western blot analyses, we recently documented significantly diminished transcription and 
translation of ODC1 in EV71-infected cells (Leong et al, 2006). VP1 interacts with 
GTAR, which contains repeated ankyrin motifs. Ankyrin repeats are one of the most 
common protein sequence motifs, with each consisting of 33 residues (Sedgwick et al, 
1999). The diversity of their sequences in different proteins leads to their efficacy as 
interaction mediators, the character and specificity of interaction being mediated by 
particular repeats (Michaely et al, 1992; Chan et al, 1993). Ankyrins are implicated in the 
CRASH (corpus callosum hypoplasia, retardation, adducted thumbs, spasticity and 
hydrocephalus) syndrome due to the disruption of ankyrin binding to the L1 vertebrate 
cell adhesion molecule (Needham et al, 2001). Ankyrin proteins are also associated with 
other cell adhesion molecules such as neurofascin, NrCAM, NgCAM and neuroglian 
which play important roles in nervous system development (Davis et al, 1993; Davis et al, 
1994). Ankyrins and neurofascin/L1/NrCAM co-localize in unmyelinated axons and 
nodes of Ranvier of myelinated axons (Kordeli et al, 1991). Disruption of binding of 
regulatory factor X with ankyrin repeats (RFXANK) to regulatory factor X-associated 
proteins (RFXAP) due to a mutation in the ankyrin groove, results in the bare lymphocyte 
syndrome (Nekrep et al, 2001). Interestingly, interactions between proteins containing 
ankyrin repeats and pathogenesis-related proteins in plants may be necessary during 
microbial infections (Wirdnam et al, 2004). During the 1998 Taiwan HFMD outbreak, 
four out of the seven patients with EV71-related acute flaccid paralysis displayed mild 
and transient manifestations of brain stem encephalitis (including myoclonic jerks, 
tremors or ataxia) before the onset of acute paralysis (Chen et al, 2001), very similar to 
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CRASH symptoms. The interaction between VP1 and GTAR was also detected in the 
nucleus, including around the nucleolus (Fig. 4.1.7). It is noteworthy that VP1 interacted 
with the GTAR polypeptide that contained six and a half repeated ankyrin motifs. The 
interacting KIAA0697 polypeptide contained only a half ankyrin motif, and interacted 
with VP1 predominantly in the cytoplasm. Our results imply that multiple ankyrin repeats 
may be necessary for nuclear localization. The viral protein–ankyrin complex may 
exploit this unique combination for movement within the cell and entry into the nucleus. 
KIAA0697 was originally identified as a cDNA clone derived from human brain 
(Ishikawa et al, 1998). Furthermore, the EV71 capsid sequence revealed two potential 
monobasic nuclear localization signal (NLS), i.e. RRK (amino acids 120–122) within 
VP1 and KHVR (amino acids 256–259), similar to those found in avian polyomavirus 
(APV) (Johne et al, 2004). As APV requires these NLS for nuclear localization ((Johne et 
al, 2004), these NLS may explain the detection of VP1 in the nucleus. In addition, two 
potential basic type NLS, i.e. KKRD (amino acids 126–129) identical to the one in 
poliovirus (Sharma et al, 2004), and KIKKGKSR (amino acids 167–174) within the 3D 
polypeptide were identified in EV71. Electron microscopy of cells infected with certain 
enteroviruses reveals that crystals or virus-like particles can be observed in the less 
electron-dense area in the center of the nucleus after the margination of chromatin (Anzai 
et al, 1969; Kawanishi et al, 1978). Poliovirus can shut down host cell transcription in 
neighboring uninfected cells, possibly through accumulation of viral proteins in nuclei 
(Bossart et al, 1984). Cell damage is not necessary related to the quantity of infectious 
virus finally produced but a reflection of the amount of intracellular virus-controlled 
protein (Godman et al, 1966). Evidence suggests that viruses may target the nucleolus 
and its cellular components to favor viral transcription, translation and perhaps alter the 
cell cycle in order to promote virus replication (Hiscox, 2002) and it has been 
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documented that transcription and translation can both occur in the nucleus (Iborra et al, 
2001). Therefore, it is not surprising to observe EV71 VP1 localization in the nuclei and 
around the nucleoli (Fig. 4.1.9). Many other viruses like arterivirus, Newcastle disease 
virus and Human parainfluenza virus type 2 were reported to require interaction with the 
nucleus for its viral functions (Tijms et al; 2002, Peeples et al, 1992, Watanabe et al, 
1996). Other viral proteins, like coronavirus nucleoprotein, HIV-1 Rev protein, CMV 3A 
protein, etc, have also been shown to localize to the nucleolus and sub-nuclear 
compartment of the cell (Hiscox, 2002). Whether the presence of EV71 VP1 in the 
nucleus is due to its translocation from the cytoplasm or its translation in the nucleus is 
yet unclear. Being a structural protein required for packaging of the viral genome, VP1 is 
synthesized in large amounts during productive infection, and is likely to interact 
intimately with specific cellular proteins. Interactions between microbial virulence factors 
and cellular proteins are specific in infected cells (Karimova et al, 2002). Through its 
interactions with ODC1, GTAR and KIAA0697, EV71 may manipulate and/or disrupt 
normal host functions e.g. cell growth, synthesis machinery and immune response 
(Sharma et al, 2004). These interactions between EV71 and host cellular proteins may 
facilitate a better understanding of cytopathic effect, and ultimately neurological 






Yeast two-hybrid screening identifies GRIM-19 as an interactor of U95. 
The pGBKT7-U95 plasmid construct was employed as the bait in the yeast two-
hybrid mating experiments using the pre-transformed bone marrow cDNA library. The 
GRIM-19 interacting clones (with the largest spanning nucleotides 307-922, GenBank 
accession no. NM_015965) exhibited the strongest β–galactosidase activity compared 
with the positive control (refer to Fig. 4.1.2 as an example). GRIM-19 constituted the 
most frequently appearing positive clones (41 out of a total of 210), and was thus selected 
for further analysis. 
U95 interacts with GRIM-19 in human MT-4 cells. 
Co-immunoprecipitation experiments were conducted to confirm the interaction 
between U95 and GRIM-19 in MT-4 cells. Western blot analysis revealed that the U95 
protein (~70 kDa) co-immunoprecipitated the GRIM-19 protein (~20 kDa), thereby 
confirming their interaction in MT-4 cells (Fig. 4.2.1). The total cell lysate from MT-4 























































FIG. 4.2.1.  Co-immunoprecipitation of HHV-6B U95 and human GRIM-19 
proteins in MT-4 cells. MT-4 cells were transfected with pCMV-HA-U95 and/or 
pCMV-Myc-GRIM-19 constructs. Mock controls were mixed lysates from cells 
transfected with the plasmids expressing either the HA or Myc tags only. (A) 
Immunoprecipitation (IP) of the cell lysates with anti-HA polyclonal antibody was 
performed, except for the Myc-GRIM-19 lysate which acted as the positive control for 
Western blot with anti-Myc. (B) Immunoprecipitation (IP) of the cell lysates with anti-
Myc monoclonal antibody was performed, except for the HA-U95 lysate which acted as 
the positive control for Western blot with anti-HA. The precipitates were fractionated 
through Tris-glycine SDS-PAGE (12%), and subjected to Western blot analysis using 
anti-HA antibody or anti-Myc antibody to detect HA-U95 or Myc-GRIM-19, 
respectively. 
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Co-localization of U95, GRIM-19 and mitochondria in MT-4 cells. 
The interaction between U95 and GRIM-19, as well as their intracellular location 
were further verified by confocal microscopy. Immunofluorescence staining using 
specific antibodies revealed strong perinuclear staining, and confirmed their co-
localization predominantly in the mitochondria (Fig. 4.2.2A-C). MT-4 cells transfected 
with the empty expression vectors served as negative controls (Fig. 4.2.2D-F). In cells 
transfected with the pCMV-HA-U95 construct only, immunofluorescent staining of HA-
U95 and endogenous GRIM-19 revealed co-localization, consistent with the results 
involving dual transfections (Fig. 4.2.3). Furthermore, specific staining of mitochondria 
verified their co-localization with endogenous GRIM-19. 
 
U95-shRNA treatment downregulates the transcription of U95. 
To verify that the U95-shRNA sequence was both specific and effective, real-time 
RT-PCR experiments were performed on mock-infected and HHV-6B-infected MT-4 
cells transfected with shRNA prior to flow cytometry. Fig. 4.2.4 shows a significant 
reduction in the U95 transcription level of U95-shRNA-treated samples especially at 4 h 
post-treatment, compared to untreated HHV-6-infected MT-4 cells. Moreover, less 
cytopathic effect (i.e. syncytial formation) was observed. The G3PDH housekeeping gene 
served as the reference transcript for RT-PCR which revealed a negligible difference in 
CT values between infected and mock-infected samples, thereby justifying its use for 













Fig. 4.2.2  Intracellular co-localization of HHV-6B U95 with GRIM-19. MT-4 cells 
were co-transfected with pCMV-Myc-GRIM-19 and pCMV-HA-U95 constructs, fixed, 
immunolabeled and examined by immunofluorescent microscopy. Detection of (A) 
Myc-GRIM-19 with mouse anti-Myc antibody and (B) HA-U95 with rabbit anti-HA 
antibody. The secondary antibodies were FITC-tagged anti-mouse antibody and 
rhodamine phallioidin-tagged anti-rabbit antibody, respectively. (C) Co-localization was 
observed by superimposing panels A and B. To serve as negative controls, MT-4 cells 
were co-transfected with empty pCMV-Myc and pCMV-HA vectors, fixed, 
immunolabeled and examined by immunofluorescent microscopy. Reaction with (D) 
mouse anti-Myc antibody and (E) rabbit anti-HA antibody. The secondary antibodies 
were FITC-tagged anti-mouse antibody and rhodamine phallioidin-tagged anti-rabbit 




Fig. 4.2.3  Co-localization of HHV-6B U95 with endogenous GRIM-19 in MT-4 cells. 
MT-4 cells were transfected with the pCMV-HA-U95 construct, immobilized onto glass 
slides using a cytospin, fixed, immunolabeled, and examined by immunofluorescent 
microscopy. (A) Detection of HA-U95 with rabbit anti-HA antibody and counter-labeled 
with FITC-tagged anti-rabbit antibody. (B, E) Detection of endogenous cellular GRIM-19 
by mouse monoclonal antibody and counter-labeled with rhodamine phallioidin-tagged 
anti-mouse antibody. (C) Co-localization displayed by superimposing panels A and B. (D) 
Mitotracker Green FM dye staining of mitochondria as long and tubular organelles 
































Cell+HHV6                            Cell+HHV6+scrambled (1 hr)      Cell+HHV6+siRNA (1 hr)          Cell+HHV6+scrambled (4 hr)     Cell+HHV6+siRNA (4 hr)
 
Fig. 4.2.4.  Real-time RT-PCR analyses of relative U95 mRNA expression levels 
in HHV-6B-infected MT-4 cells following U95-shRNA treatment compared with 
controls. HHV-6B-infected MT-4 cells were transfected with U95-shRNA construct 
or with the control scrambled-shRNA construct after infection for 1 h. Real-time RT-
PCR was performed at 1 and 4 h following shRNA transfection. Samples were 
normalized against the G3PDH housekeeping gene, and with untransfected but HHV-
6B infected MT-4 cells at each respective time-point as the reference sample (i.e. fold-
change of 1 for U95 transcription). Statistical analyses were then performed, with P 
values of <0.05 denoting significant differences. 
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Ultrastructural evidence for the effect of HHV-6B infection on mitochondria. 
To understand the implication of the U95-GRIM-19 protein complex on 
mitochondria, both HHV-6B-infected as well as HHV-6B-infected but U95-shRNA-
treated MT-4 cells were subjected to transmission electron microscopy. The mitochondria 
of HHV-6B-infected cells exhibited swelling and less convoluted cristae (Fig. 4.2.5A). In 
contrast, HHV-6B-infected but U95-shRNA-treated MT-4 cells displayed less swelling of 
the mitochondria, with the majority showing more convoluted cristae (Fig. 4.2.5B). 
However, no other abnormal phenotypic changes were observed in both populations of 
mitochondria. To determine the progression and frequency of these structural 
abnormalities of the mitochondria in HHV-6B-infected cells compared with uninfected 
cells, mitochondrial organelles were monitored by electron microscopy at 0, 1, 4 and 7 h 
post-infection. Alterations in mitochondrial structures of infected cells were 
comparatively more apparent as the infection progressed (Fig. 4.2.5C-G). Using electron 
microscopy to count the number of normal and abnormal mitochondria in ten random 
cells per group and obtaining the mean percentages, it was evident that the percentage of 
abnormal mitochondria steadily increased with time of infection (Table 1). 
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Fig. 4.2.5. Transmission electron micrographs of HHV-6B-infected cells 
without and with U95-shRNA treatment. (A) After 5 h of infection of MT-4 cells 
with HHV-6B, typical features of mitochondrial swelling (SW) with severe 
disruption of mitochondrial structures showing myelin-like figures (MY), and loss 
of cristae were observed. (B)  After 1 h following HHV-6B infection, MT-4 cells 
were transfected with U95-shRNA. At 4 h post-RNAi, swelling of the mitochondria 
was significantly reduced, and numerous cristae (CR) could be clearly observed. 
The magnification was 50,000 times. (C) At the time of infection of MT-4 cells with 
HHV-6B, and (D) at 1 h post-infection, little or no disruption of mitochondrial 
structures was observed. (E) At 4 h and (F) at 7 h post-infection, there were 
increasingly severe structural abnormalities of mitochondria including myelin-like 
figures (MY), and loss of cristae. (G) At 7 h, uninfected MT-4 cells generally 
displayed normal mitochondrial structures. The scale bars at the bottom left corners 
are equivalent to 1 µm. 
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Table 1. Analysis of the frequency of structural abnormalities of mitochondria in HHV-6B–infected versus uninfected MT-4 cells at 0, 1, 4 
and 7 h post-infection. 
 
 





























0 70 3 73 4.11 86 6 92 6.52 
1 36 4 40 10.00 90 5 95 5.26 
4 46 15 61 24.59 66 3 69 4.35 
7 34 16 50 32.00 63 4 67 5.97 
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HHV-6B infection and U95-shRNA treatment significantly influence mitochondrial 
membrane potential.  
To determine if the interaction between U95 and GRIM-19 has an impact on 
mitochondrial function, HHV-6B-infected versus uninfected MT-4 cells were assayed for 
their mitochondrial transmembrane potential activity. The latter is a very good indication 
of the physiological state of both cells and mitochondria. Unstained cells were included 
to exclude signals from cells demonstrating autofluorescence (Fig. 4.2.6A). Normal 
healthy cells were stained with the dye, DiOC2(3), and subjected to fluorescence at an 
excitation wavelength of 488 nm. Signals from both 530/30 nm bandpass and 650 nm 
longpass filters could be detected as green and red fluorescence, respectively (Fig. 
4.2.6B). However, when MT-4 cells were infected with live HHV-6B, only green 
fluorescent signals could be detected (Fig. 4.2.6C), with the decrease in mitochondrial 
membrane potential being accompanied by a shift from red to green fluorescence. When 
HHV6B-infected cells were transfected with U95-shRNA, there was a reversion of the 
fluorescent signal comparable to that of normal healthy cells (Fig. 4.2.6D). The negative 
control experiment involving HHV6B-infected cells that were transfected with the 
scrambled-shRNA construct could not restore the mitochondrial transmembrane potential, 
with a shift to green fluorescence (Fig. 4.2.6E). The percentages of cells in different 
treatment and control groups emitting red, green or both fluorescent signals are 
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Fig. 4.2.6. Assessment of mitochondrial membrane potential by the MitoProbe 
DiOC2(3) assay. MT-4 cells were analyzed by flow cytometry using 488 nm excitation, 
with 530/30 nm bandpass and 650 nm longpass detection filters. Cells were resuspended 
in PBS and the distribution of fluorescent signals (logarithmic scale) of 20,000 cells was 
observed. The x-axes of the left and right panels depict the intensity of green and red 
fluorescence, respectively. Each y-axis indicates the number of cells, while each area 
under the curve is equivalent to 20,000 cell events. (A) Unstained MT-4 cells served as a 
control to exclude auto-fluorescence. (B) DiOC2(3)-stained uninfected MT-4 cells. (C) 
DiOC2(3)-stained HHV-6B-infected MT-4 cells showing reduction in red fluorescence 
signals. (D) DiOC2(3)-stained HHV-6B-infected MT-4 cells subjected to U95-shRNA 
treatment at 1 h post-infection. (E) DiOC2(3)-stained HHV-6B infected MT-4 cells 
subjected to scrambled-shRNA treatment at 1 h post-infection indicating decreased red 
fluorescence signals. (F) Effect of HHV-6B RNAi treatment on mitochondrial membrane 
potential in HHV-6B-infected MT-4 cells. Bar chart illustrating the percentages of cells in 
different treatment and control groups emitting red, green or both fluorescent signals by 
flow cytometry. 
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        Many studies have characterized the members of the US22 family but there are few 
functional studies pertaining to their interaction with mammalian cellular proteins. Being 
a relatively recently identified member of this family, U95 is known only as an IE protein 
(Takemoto et al, 2001). IE genes are important as they are the first to be transcribed and 
translated into functional proteins to aid in the downstream processes of viral infection. 
To address the functional aspects of an IE gene during infection, U95 of HHV-6B was 
used as bait in the yeast two-hybrid assay to screen for potential interacting human 
proteins. GRIM-19 was thus identified as a strong interactor of the U95 protein. The U95 
protein could immunoprecipitate the GRIM-19 protein from the total cell lysate and vice 
versa, further demonstrating their strong interaction. To verify this interaction, the 
immunofluorescence assay revealed distinct co-localization in the perinuclear region, 
predominantly in the mitochondria. Previous studies have demonstrated localization of 
GRIM-19 primarily in the mitochondria, and have indicated that GRIM-19 is essential for 
early embryonic development (Huang et al, 2004). GRIM-19 is a small protein that 
promotes cell death induced by IFN-β and RA (Angell et al, 2000). Interestingly, vIRF1 
of Kaposi's sarcoma-associated HHV-8, human papillomavirus type 16 E6 and SV40 LT 
antigen also bind GRIM-19, suggesting that this is a target for certain viral proteins 
(D’Agostino et al, 2005; Seo et al, 2002). Downregulation of GRIM-19 by antisense 
treatment culminated in growth advantage to cells in the presence of IFN/RA, and cells 
that express moderate levels of GRIM-19 are significantly more susceptible to the 
cytotoxic action of IFN/RA (Angell et al, 2000; Seo et al, 2002). Knockdown of GRIM-
19 and NADH dehydrogenase ubiquinone Fe-S protein 3 (the two subunits of the 
mitochondrial respiratory chain complex I) confers resistance to IFN/RA-induced 
apoptosis and decreased production of reactive oxygen species (Huang et al, 2007). On 
the other hand, upregulation of GRIM-19 results in enhanced caspase-9 activity and 
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apoptotic cell death response to IFN/RA treatment (Angell et al, 2000). Interestingly, 
GRIM-19 interacts with endogenous nucleotide oligomerization domain 2 (NOD2) which 
mediates innate mucosal responses and functions as an antibacterial factor that limits the 
survival of invasive intracellular bacteria (Barnich et al, 2005).  
Cells infected with HHV-6B exhibit the typical appearance of cytopathic effects, 
becoming large, balloon-type cells or forming syncytia. Cell death almost always results 
although it is still unclear whether by necrosis or apoptosis. Cell death through the 
apoptotic pathway was indicated by upregulation of the caspase-3 gene during HHV-6 
infection (Mayne et al, 2001). The release of cytochrome C from mitochondria can also 
ultimately lead to activation of caspase-9, then caspase-3 and apoptosis. While numerous 
studies indicate that apoptosis is mediated by various viral infections, the precise 
mechanisms of apoptotic death in virus-infected cells have not been clearly demonstrated. 
Some studies conclude that apoptosis is rarely observed in virus-infected cells, e.g. HIV-
1-producing cells, and that HIV-1 RNA is rarely detected in apoptotic cells (Finkel et al, 
1995). Moreover, it is documented that apoptosis occurs predominantly in uninfected 
CD4+ T-cells but not in productively HHV-6-infected cells (Inoue et al, 1997). HHV-6 
also prevents monocytes from undergoing spontaneous apoptosis during the initial 72 h 
of culture (Janelle et al, 2006). Our results indicate that apoptosis is unlikely to be the 
major event during the earlier phase of HHV-6B infection of MT-4 cells. Electron 
micrographs of HHV-6B infected cells (Fig. 4.2.5) revealed the swelling of the 
mitochondria. The other changes in mitochondrial ultrastructure and morphology 
indicative of mitochondrial degeneration were the loss of cristae and appearance of 
myelin-like figures (Miguet-Alfonsi et al, 2002; Shishido et al, 2003). No other structural 
disruptions were observed in the infected cells; neither any typical signs of apoptosis 
including membrane blebbing, nuclear fragmentation, and chromatin condensation. RNAi 
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against the U95 gene at 1 h post-infection restored the normal phenotypic appearance of 
the mitochondria without any significant loss of cristae. 
In order to ascertain the significance of the U95-GRIM-19 interaction in MT-4 cells, 
prevention of the protein complex formation was achieved using shRNA treatment 
targeting U95. Specific and efficacious RNAi targeting against the U95 gene in vitro was 
confirmed by real-time RT-PCR. U95-shRNA treatment for 4 h resulted in a highly 
significant reduction of U95 mRNA expression of 27.6-fold (P < 0.0002) compared to 
treatment with the control scrambled-shRNA sequence. 
GRIM-19 is an essential component of the oxidative phosphorylation system. 
Oxidative phosphorylation activity is closely related to the electrical potential difference 
across the outer and inner membrane of the mitochondria. This potential is a key 
indicator of cellular viability as it reflects the pumping of hydrogen ions across the inner 
membrane during the process of electron transport, i.e. the driving force behind ATP 
(Adenosine triphosphate) production. ATP is the major source of usable energy in all cell 
metabolisms. This electric potential difference or mitochondria transmembrane potential 
difference can be demonstrated by the flow cytometry analysis using the dye DiOC2(3). 
This membrane-potential-sensitive cyanine dye can penetrate the cytosol of eukaryotic 
cells and accumulates primarily in mitochondria with active membrane potentials, 
producing bright red and green fluorescence (Galluzzi et al, 2007; Shapiro et al, 2000). 
Due to the nature of this dye, it has affinity for the charges on the membrane of active 
mitochondria and hence, is limited to analysis with live samples only. DiOC2(3) staining 
intensity decreases with decreased mitochondrial transmembrane potential, accompanied 
by a shift from red to green fluorescence. The respiratory activity of the mitochondria 
during HHV-6B infection is a good indication of the physiological state of the cell. The 
effect of preventing the U95-GRIM-19 interaction via U95-shRNA treatment was 
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documented using flow cytometry experiments with the DiOC2(3) dye. DiOC2(3)-stained 
normal uninfected MT-4 cells with active mitochondrial membrane potential exhibited 
both red and green fluorescence. A similar profile with emission of both red and green 
fluorescence was observed with the HHV-6B-infected cells treated with U95-shRNA. In 
contrast, HHV-6B-infected cells demonstrated a disruption of the mitochondrial 
transmembrane potential, with decreased staining intensity and a shift from red to green 
fluorescent signals. Scrambled-shRNA treatment was unable to inhibit the formation of 
the U95-GRIM-19 complex, and thus displayed a similar fluorescence profile to that of 
HHV-6B-infected cells. From our data, it is clear that the effect of mitochondrial 
membrane potential loss due to HHV-6B infection can be abrogated by blocking the 
formation of the U95-GRIM-19 complex. Previous studies conclude that mitochondrial 
membrane potential collapse is an early and necessary event which plays an important 
role in apoptosis of cells (Charlot et al, 2004). Apoptotic mechanisms may involve 
alteration in mitochondrial membrane permeability and depolarization of mitochondrial 
membrane potential (Morrison et al, 2005). Increased expression of uncoupling protein 2 
in HeLa cells leads to a rapid and pronounced fall in mitochondrial membrane potential, 
culminating in oncosis which is a form of cell death induced by energy depletion (Mille 
et al, 2002). However, we have shown that mitochondrial membrane potential collapse 
due to HHV-6B infection was not accompanied by overt apoptotic events, and that the 
loss in the membrane potential during HHV-6B infection could be abolished by inhibiting 
U95 gene transcription. This beneficial effect of U95 downregulation renders U95 as a 
potentially attractive target for novel antiviral design. 
Although certain viral homologs of human cellular anti-apoptotic genes have been 
identified within the betaherpesvirinae, e.g. vbcl-2 and FLIP, none has hitherto been 
found in HHV-6B (Rartery et al, 2000). Taken together, our results indicate that the U95 
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protein binds to and may inactivate GRIM-19, thereby interfering with its regulation of 
cell death in response to IFN/RA. However, GRIM-19 is also an indispensable 
component of mitochondrial complex I that plays an essential role in mitochondrial 
function, integrity of the electron transfer chain and the oxidative phosphorylation system 
(Huang et al, 2004; Huang et al, 2007). Our data strongly suggest that U95 is directly 
responsible for the altered mitochondrial structure and function, but it is possible that 
U95 may regulate the actual agent of mitochondrial dysfunction. Such a hypothesis may 
be addressed by observing whether mitochondrial structure and function are altered in 
cells transfected with the U95 gene alone. 
Notwithstanding that the specific benefits to the virus resulting from the U95-
GRIM-19 protein complex have yet to be elucidated, it is likely that any inactivation of 
GRIM-19 by HHV-6 will lead to mitochondrial membrane potential loss and ultimately 
contribute to the cytopathic effect. The febrile illness arising from HHV-6 infection is 
particularly prevalent in early childhood, and HHV-6 reactivation is a serious problem for 
immunocompromised patients and organ transplant recipients (Krueger et al, 2006). 
Furthermore, a putative relationship between HHV-6 infection and multiple sclerosis 
(MS) has been suggested (Merelli et al, 1996). Biochemical defects in complex I activity 
may be involved in the pathogenesis of MS (Kumleh et al, 2006), and mitochondrial 
dysfunction plays a key role in progressive axonal loss in multiple sclerosis (Andrews et 
al, 2005). Future studies on the functional consequences of the interaction between U95 
and GRIM-19 are therefore warranted to better comprehend the mechanisms of HHV-6 













CHAPTER 5: CONCLUSION 
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The Yeast-Two Hybrid System in conclusion, is a valuable and simple tool to 
identify and isolate potential interacting protein partners for your protein of interest. 
Because of the ease of the assay, exploratory two-hybrid screens are usually the first 
method of choice when information of interacting proteins in vivo is desired. Since 
protein-protein interactions are critical to all cellular processes, understanding them is the 
key to understanding any biological system. 
We have so far seen the usefulness of the Yeast Two-Hybrid System in identifying 
the potential interacting protein partners for our gene(s) of interest. By complementing 
the system with analyses from the co-immunoprecipitation and indirect 
immunofluorescence experiments, we can conclude with confident that the identified 
interacting partners are indeed the interacting proteins we are looking for in vitro. We 
have also seen that there are few shortfalls of the system that must be taken into 
consideration when interpreting the results from the interactions, e.g. false-positives due 
to contamination of the screening library by genomic sequences or translation of the 
incorrect open reading frame. Moreover, if the interactors are proteins that have been 
documented with a history of being a false-positive, e.g. heat shock proteins, ribosomal 
proteins, cytochrome oxidase, proteosome subunits, ferritin, transfer RNA-synthase, 
collagen-related proteins, vimentin, inorganic pyrophosphatase and transcription factors, 
more stringent screening experiments (like plasmid linkage, co-immunoprecipitation and 
Fluorescence energy transfer (FRET)) are needed to verify the interaction.  
In the first section of the study, the binding affinity between VP1 and three human 
proteins, i.e. ornithine decarboxylase (ODC1), gene trap ankyrin repeat (GTAR), and 
KIAA0697, using the Yeast Two-Hybrid System, were demonstrated. These interactions 
were authenticated by co-immunoprecipitation experiments, and by indirect 
immunofluorescent confocal microscopy of transfected and EV71-infected Vero cells. It 
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is without doubt that the binding of VP1 to these proteins effect drastic changes in the 
infected cells since we know that ODC1 is an important enzyme since it is the first and 
rate-limiting enzyme in polyamine biosynthesis and that Ankyrin repeats are important 
motif present in a number of proteins of diverse functions including transcription factors, 
cell differentiation molecules, and structural proteins. Recent findings implicated strongly 
the association with CRASH syndrome due to the disruption of the binding of ankyrin to 
vertebrate cell adhesion molecule (L1), and Ankyrin proteins are also found to be 
associated with other cell adhesion molecules like Neurofascin, NrCAM, NgCAM and 
neuroglian, which are believed to play important roles in development of the nervous 
system . Given that VP1 is synthesized in large amounts during productive infection, 
these viral-host protein interactions may provide insights into the role of VP1 in the 
pathogenesis of EV71 disease and its neurological complications such as acute flaccid 
paralysis and encephalitis. An enzyme assay using 14C to analysis the effect of the 
binding of EV71 VP1 to ODC1 would be interesting and highly recommended as a 
follow-up on this study. 
In the final part of the thesis, it is concluded that the U95 protein of the HHV6B 
interacts with the human GRIM19 protein. GRIM-19 was originally identified as a 
nuclear protein with apoptotic nature in the interferon (IFN) and all-trans-retinoic acid 
(RA)-induced tumor cells and it localizes to human chromosome 19p13.2. Interestingly, 
the viral interferon factor 1 (vIRF1) of Kaposi's sarcoma-associated herpesvirus and 
human papillomavirus type 16 E6 also bind GRIM19, suggesting that this is a target for 
viral proteins and also, an important protein to look into when developing anti-viral drugs. 
GRIM19 can be detected in the native form of mitochondrial complex I. Elimination of 
GRIM19 destroys the assembly and electron transfer activity of complex I and also 
influences the other complexes in the mitochondrial respiratory chain. Complex I 
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represents the largest and the least understood multimeric enzyme complex that catalyzes 
the first step in the electron transfer chain by transferring two electrons from NADH to 
ubiquinone and is coupled to the translocation of four protons across the inner 
mitochondrial membrane for ATP synthesis. GRIM-19 has also been shown to interact 
with STAT-3 (signal transducers and activators of transcription) in various cell types and 
to function as a negative regulator of STAT-3 by preventing its translocation into the 
nucleus and incidentally transcription of its target genes. This interaction inhibits STAT-3 
nuclear translocation stimulated by EGF (epidermal growth factor). The binding of U95 
to GRIM19 may somehow alter the binding ability of latter to complex I, resulting in 
IFN/RA-induced cell death or its absence/inactivated state confers a strong resistance 
against induced death caused by these two agents. Taken together, it seems that what we 
are looking at is an on-going evolutionary race between pathogen and host; the first 
evolving human anti-apoptotic homologues and the latter, adopting multiple pathways 
leading to death. Given the significance of the U95-GRIM-19 interaction, an analysis of 
the structural and functional alterations on the mitochondria when MT-4 cells are 
transfected with the U95 construct should be pursued. Moreover, the effect of the 
knockdown of the GRIM-19 gene during HHV-6 infection should be carried out. 
Both DNA and protein microarray analysis should be conducted to determine if 
cells infected by EV71 and /or HHV6B, producing VP1 or U95, have up, down, or null 
effect on the expression level of their interactors, and other genes. 
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Table 2. Genetics and cell infection of human herpesvirus 6 (HHV-6) and human herpesvirus 7 
(HHV-7)  
  HHV-6 HHV-7 
Tropism  T-lymphotropic.  
A broad host-cell range can be infected in vitro 
(particularly for HHV-6A), which includes 
primary T cells, NK cells and astrocytes, as 
well as continuous cell lines of T cells, B cells, 
megakaryocyte and glial lineages.  
T-lymphotropic.  
Tropism is restricted to: CD4+ T cells and the 
SupT1 cell line.  
Variants  HHV-6A, HHV-6B.  
HHV-6A might have a different host-cell 
range/pathogenesis and is ~5% divergent at the 
nucleotide level from HHV-6B.  
None known. 
Receptor  
(for binding to cells 
and entry) 
Binding through CD46.  
The broad host-cell tropism of HHV-6 
suggests that either (1) the receptor is 
ubiquitous or (2) more than one molecule can 
be used for virus entry. 
CD4 is a necessary receptor component, but 
is not ‘sufficient’ for virus entry. 
Cell markers HHV-6 can induce expression of CD4 on some 
CD4– cells. 
HHV-7 induces loss of cell- surface CD4. 
Monocyte infection HHV-6 can persist in monocytes. HHV-7 does not infect monocytes. 
Genome size  U1102 strain of HHV-6A is 159 kb with DRs 
of 8 kb. 
JI strain of HHV-7 is 145 kb with DRs of 6 
kb. 
AAV-2 rep gene 
homologue 
ORF U94 is a homologue of AAV-2 rep. No homologue of AAV-2 rep. 
Unique virion 
glycoprotein 
Encodes gp105, a viral glycoprotein that 
derives from a highly spliced mRNA spanning 
multiple ORFs at the right end of the unique 
segment of the HHV-6 genome (U96-100). 
gp105 is a major virion component and 
contains a major neutralising antibody epitope.
Predicted to encode a homologue of gp105.  
Shared properties of HHV-6 and HHV-7  
Replication In PBMCs, replication is slow and lytic; syncytia are induced. 
Genetics and viral 
genome 
HHV-6 and HHV-7 are closely related and co-linear.  
Telomeric DNA is present near (not at) the genomic termini.  
They share a common oriLyt organisation, similar to HSV-1 oriS. 
They encode:  
(1) U73: a homologue of the HSV-1 origin-binding protein;  
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(2) U12 and U51: two homologues of cellular G-protein-coupled receptors;  
(3) U20 and U85: two genes with homology to genes of the immunoglobulin family (U85 is 
homologous to OX-2, a molecule that mediates a recently described T-cell co-stimulatory 
pathway); 
(4) gB, gH and gL: homologues of three of the four essential virion glycoproteins in HSV-1. 
They do not encode: 
(1) a homologue of gD, the receptor-binding HSV-1 glycoprotein.  
Abbreviations used: AAV = adeno-associated virus; DR = direct repeat; HHV = human herpesvirus; HSV-1 = herpes 
simplex virus type 1; kb = kilobase; NK = natural killer; ORF = open reading frame; PBMCs = peripheral blood 
mononuclear cells. 
(Courtesy of Stephen Dewhurst, Department of Microbiology and Immunology, and Cancer Center, University of 
Rochester Medical Center). 
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HHV-6 gene  
(and gene product)  
Homologue in 
HHV-7 
(% amino acid 
identity with HHV-6) 
Homologue 
in HCMV  
Homologue 
in HSV-1  
3– 
338  
-  112  LT1        
        H1  
(169 amino acids 
unique)  
    
501– 
794  
+  98  DR1  
(contains CxC motif, member of HCMV 
US22 gene family  
DR1  
(44%)  
    
791– 
2653  
+  621  DR2  
(member of HCMV US22 gene family)  
DR2  
(37%)  
US26    
        H2  
(7 amino acids 
unique)  
    
2401– 
2979  
-  193  DR3        
2746– 
3048  
+  101  DR4        
3734– 
4171  
-  146  DR5        
4725– 
5036  
+  104  DR6  
(contains CxC motif, member of HCMV 
US22 gene family)  
DR6  
(59%)  
    
5629– 
6720  
+  364  DR7  
(transforming and a transactivator, member of 
HCMV US22 gene family)  
DR7  
(61%)  
US22    
        H3  
(82 amino acids, 
unique)  
    
        H4  
(98 amino acids 
unique) 
    
7237_ 
7569  
+  111  DR8        
7467_ 
8432  
-  322  LJ1 
(spans telomeric repeats) 
      
8245– 
8616  
+  124  U1        
8716– 
9816  
-  367  U2 
(member of HCMV US22 gene family)  
U2  
(51%)  
UL23    
10155– -  374  U3 U3  UL24    
 113
11276  (member of HCMV US22 gene family)  (49%)  
11485– 
13092  
-  536  U4  U4  
(59%)  
UL27    
13214– 
14548  
-  445  U5  U5/7  
(50)  
UL27    
14619– 
14867  
+  83  U6        
14908– 
15936  
-  343  U7 
(member of the HCMV US22 gene family)  
U5/7  
(61%)  
UL28    
16021– 
17091  
-  357  U8 
(member of the HCMV US22 gene family)  
U8  
(51%)  
UL29    
17238– 
17552  
-  105  U9        
17604– 
18914  
+  437  U10  U10  
(52%)  
UL31    
18966– 
21578  
-  871  U11 
(pp100, a structural phosphoprotein)  
U11  
(31%)  
UL32    
21856– 
22812  
+  319  U12  




UL33    
22898– 
23218  
+  107  U13  U13  
(37%)  
    
23316– 
25145  
+  610  U14 
(the major tegument protein)  
U14  
(54%)  
UL35    
25660– 
25992  
-  111  U15  U15  
(64%)  
    
26262– 
27116  
-  285  U16 
(IE-B transactivator, might be spliced, 
member of the HCMV US22 family) 
U16  
(57%)  
UL36x2    
26948– 
27349  
-  134  U17 
(IE-B transactivator, might be spliced, 
member of the HCMV US22 family ) 
U17  
(40%)  
    
28508– 
29389  
-  294  U18 
(IE -B,  
homologous to HCMV IE glycoprotein)  
U18  
(44%)  
UL37x3    
29649– 
30818  
-  390  U19  U19  
(40%)  
UL38    
31069– 
32337  
-  423  U20 




    
32340– 
33641  




    
33739– 
34347  
-  203  U22 
(a glycoprotein)  




-  237  U23 
(a glycoprotein, homology to EHV-1 gJ)  
U23  
(29%)  
    
35392– 
35655  
-  88  U24 
(a glycoprotein; might have a spliced exon)  
U24  
(37%)  
    
35864– 
36814 
-  317  U25 
(might be a transactivator, member of the 
HCMV US22 gene family)  
U25  
(49%)  
UL43    
36922– 
37809  
-  296  U26  U26  
(30%)  
    
37797– 
38978  
-  394  U27 
(pp41, pol processivity factor)  
U27  
(68%)  
UL44  UL42  
39020– 
41434  
-  805  U28 
(large subunit of the ribonucleotide reductase) 
U28  
(47%)  
UL45  UL39  
41457– 
42356  
-  300  U29 
(minor capsid protein)  
U29  
(53%)  
UL46  UL38  
41884– 
45132  
+  1083  U30 
(involved in capsid assembly)  
U30  
(46%)  
UL47  UL37  
45150– 
51383  
+  2078  U31 
(large tegument protein)  
U31  
(46%)  
UL48  UL36  
51455– 
51721  
-  89  U32  U32  
(66%)  
  UL35  
51723– 
53135  
-  471  U33 
(a virion protein) 
U33  
(59%)  
UL49    
53086– 
53916  
-  277  U34 
(might be a virion protein)  
U34  
(59%)  
UL50  UL34  
53933– 
54253  
-  107  U35  U35  
(58%)  
UL51  UL33  
54252– 
55706  
+  485  U36 
(might be a virion protein)  
U36  
(58%)  
UL52  UL32  
55710– 
56504  
+  265  U37 
(might be a nuclear phosphoprotein)  
U37  
(63%)  
UL53  UL31  
56550– 
59588  
-  1013  U38 
(DNA polymerase)  
U38  
(67%)  
UL54  UL30  
59588– 
62080  
-  831  U39 
(glycoprotein B)  
U39  
(56%)  
UL55  UL27  
62034– 
64214  
-  727  U40 
(a transport protein)  
U40  
(56%)  
UL56  UL28  
64222– 
67620  
-  1133  U41 
(a major DNA binding protein)  
U41  
(63%)  
UL57  UL29  
69054– 
70598  




UL69  UL54  
70823– 
73405  
-  861  U43 








+  214  U44  U44  
(59%)  
UL71  UL51  
74088– 
75218  




UL72  UL50  
75291– 
75545  
+  85  U46 
(a membrane-secreted protein) 
U46  
(53%)  
UL73  UL49a  
75912– 
77867  
-  652  U47 
(a glycoprotein)  
U47  
(25%)  
UL74    
78034– 
80118  
-  695  U48 
[glycoprotein H, (gH)]  
U48  
(39%)  
UL75  UL22  
80277– 
81035  
+  253  U49 
(a fusion protein)  
U49  
(52%)  
UL76  UL24  
80812– 
82479  
+  556  U50 
(a virion protein)  
U50  
(55%)  
UL77  UL25  
82574– 
83479  
+  302  U51 
( GCR, homologue of an opioid receptor )  
U51  
(36%)  
UL78    
83498– 
84274  
-  259  U52  U52  
(56%)  
UL79    
84281– 
85867  
+  529  U53) 
(a protease-assembly protein  
U53  
(52%)  
UL80  UL26  
86051– 
87427  
-  459  U54 
(a tegument transactivator) 
U54  
(41%)  
UL82/83    
87505– 
88803  
-  433  U55 
(might have a replication function)  
U55A  
(33%) 
and U55B  
(21%)  
UL84    
88983– 
89873  
-  297  U56 
(a capsid protein)  
U56  
(65%)  
UL85  UL18  
89875– 
93912  
-  1346  U57 
(a major capsid protein)  
U57  
(68%)  
UL86  UL19  
93924 
96242  
+  773  U58  U58  
(61%)  
UL87    
96239– 
97291  
+  351  U59  U59  
(39%)  
UL88    
97288– 
98256  
-  323  U60  
(part of U60-66 late spliced gene, might be a 
DNA packaging protein)  
U60  
(76%)  
UL89x2  UL15x2  
98231– 
98578  
-  116  U61        
98427– 
98684  
+  86  U62  U62  
(51%)  
UL91    
98632– 
99282  
+  217  U63  U63  
(72%)  
UL92    
99260– +  443  U64  U64  UL93  UL17  
 116
100588  (41%)  
100545– 
101552  
+  336  U65  U65  
(60%)  
UL94  UL16  
101569– 
102486  
-  306  U6 
(part of U60- 66 late spliced gene, might be a 
DNA packaging protein)  
U66  
(62%)  
UL89x1  UL15x1  
102458– 
103519  
+  354  U67  U67  
(52%)  
UL95  UL14  
103519– 
103863  
+  115  U68  U68  
(49%)  
    
103866– 
105554  
+  563  U69 
(ganciclovir kinase, a phosphotransferase)  
U69  
(54%)  
UL97  UL13  
105562– 
107028  
+  489  U70 
alkaline exonuclease  
U70  
(52%)  
UL98  UL12  
106965– 
107198  
+  78  U71  U71  
(53%)  
    
107278– 
108312  
-  345  U72 




UL100  UL10  
108325– 
110667  
+  781  U73 
(origin-binding protein)  
U73  
(58%)  
  UL9  
110636– 
112624  
+  663  U74 
(part of the helicase /primase complex)  
U74  
(41%)  
UL102  UL8  
112659– 
113408  
-  250  U75  U75  
(46%)  
UL103  UL7  
113317– 
115305  
-  663  U76 
(might be a virion protein)  
U76  
(60%)  
UL104  UL6  
115100– 
117574  
+  825  U77 




UL105  UL5  
        H5  
(166aa; unique)  
    
118709– 
119038  
-  110  U78        
120164– 
121198  
+  345  U79 
(a putative replication protein)  
U79  
(45%)  
UL112    
        H6  
(C-terminus of U79)  
(49%)  
    
121170– 
121763  
+  198  U80 
(a putative replication protein)  
  UL113    
121810– 
122577  
-  256  U81 
(a uracil-DNA glycosylase)  
U81  
(59%)  
UL114  UL2  
122653– -  251  U82 U82  UL115  UL1  
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123405  [glycoprotein L (gL)]  (40%)  
123528– 
123821  
+  98  U83 
(contains CC motif)  
      
123925– 
124953  
-  343  U84  U84  
(47%)  
UL117    
124981– 
125853  
-  291  U85 
(a glycoprotein, homologue of OX-2)  
U85  
(38%)  
    
125992– 
128136  
-  715  U86 
(IE-A, homology with HCMV IE2)  
U86  
(41%)  
UL122    
127551– 
130043  
-  831  U87  
(IE-A transactivator, has pro-repeats, charged) 
      
131034– 
132275  
+  414  U88 
(IE-A transactivator, has cys-repeats)  
      
133091– 
135610  
-  840  U89 
(IE-A transactivator)  
U89  
(36%)  
    
135664– 
135948  
-  95  U90 
(IE-A, has a spliced exon)  
U90  
(39%)  
    
136485– 
136826  
-  114  U91 
(IE-A, might be a spliced antisense IE-1)  
U91  
(27%)  
    
        H7  
(427 amino acids, 
unique,  
has DraI repeats)  
    
138052– 
138492  
-  147  U92 
(has KpnI repeats) 
      
138534– 
139124  
-  197  U93 
(has KpnI repeats)  
      
141394– 
142866  
-  491  U94 
(homologue of AAV Rep)  
      
142941– 
146306  
+  1122  U95 
(homologue of MCMV IE2, member of the 
HCMV US22 gene family)  
U95  
(30%)  
    
        H8  
(90 amino acids, 
unique)  
    
146641– 
146940  
-  100  U96 
(glycoprotein gp82/105, has spliced mRNA)  
      
147808– 
148077  
-  90  U97 
(glycoprotein gp82/105, has spliced mRNA)  
      
148744– 
149391  
-  296  U98 
(glycoprotein gp82/105, has spliced mRNA)  
U98  
(31%)  
    
149485– 
149766  
-  94  U99 
(glycoprotein gp82/105, has spliced mRNA)  
U99  
(37%)  
    
149868– -  190  U100 U100      
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150437  (glycoprotein gp82/105, has spliced mRNA)  (24%)  
151140– 
151571  
-  144  RJ1 
(it spans telomeric repeats)  
      
        H1'  
(169 amino acids, 
unique)  
    
151734– 
152027  
+  98  DR1' 
(contains CxC motif, member of the HCMV 
US22 gene family) 
DR1'  
(44%)  
    
152024– 
153886  
+  621  DR2' 
(member of HCMV US22 gene family)  
DR2'  
(37%)  
US26    
        H2'  
(79 amino acids 
unique)  
    
153634– 
154212  
-  193  DR3'        
153979– 
154281  
+  101  DR4'        
154967– 
155404  
-  146  DR5'        
155958– 
156269  
+  104  DR6' 
(contains CxC motif, member of the HCMV 
US22 gene family)  
DR6'  
(59%)  
    
156862– 
157953  
+  364  DR7' 
(transforming, transactivator, member of 
HCMV US22 gene family)  
DR7'  
(61%)  
    
        H3'  
(82 amino acids 
unique)  
US22    
        H4'  
(9 amino acids 
unique)  
    
158470– 
158802  
+  111  DR8'        




Table 4: Primers designed for use specifically in the Yeast Two-Hybrid experiments. The engineered 
restriction endonuclease sites in the cloning primers are highlighted in red. The start and stop codon of all ORFs is 
represented in bold. Additional bases at the 5’ ends of the restriction endonuclease sites are represented in italics. 
Primer name  Sequence (5’-3’) 
FORBID (sense) BD vector 
screening primer 
TCATCGGAAGAGAGTAGTAACAAAGG 
FAD (sense) AD vector 
screening primer 
ATGAAATGAAGATACCCCACCAAACC 














Table 5: Primers designed for VP1 and U95 in the Yeast Two-Hybrid experiments. The engineered restriction 
endonuclease sites in the cloning primers are highlighted in red. The start and stop codon of all ORFs is represented 
in bold. Additional bases at the 5’ ends of the restriction endonuclease sites are represented in italics. 
Primer name  Sequence (5’-3’) 
VP1F (sense) CTTATGGCCATGGAGGCCGGGGATAGGGTGGCAGAT 
VP1R (anti-sense) ATGTCGACTCAAAGGGTAGTGATGGCATTAC 
U95F-SfiI (sense) TGACTAAGCTGTTACTAATATCACTGGCCATTATGGCC 
ATGTCTTCAAATCTGG 
U95R-PstI (anti-sense) TATCAAAGGCTGCAG TTATTTACCTTCCTGAG 
U95R-NotI (anti-sense) TATTAATTGCGGCCGC TTATTTACCTTCCTGAG 
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APPENDIX 
1. LB medium (LB) 
Bacto-Tryptone      10 grams 
Bacto-yeast extract      5 grams 
NaCl        10 grams 
ddH2O to       1 litre 
Note: adjust pH to 7.0 and autoclave to sterilize 
2. Dulbecco modified eagle’s minimum essential medium with 10% fetal calf 
serum (DMEM10) 
Dulbecco modified eagle’s medium (Gibco)   1 Packet 
HEPES (Gibco)      2% 
NaHCO3        2% of 7% stock 
FCS        10% 
The solution was then adjusted to 1L and filtered through a 0.22µm syringe filter. 
3. RPMI (1640) 10 
RPMI (1640) (Gibco)      1 Packet 
HEPES (Gibco)      2% 
NaHCO3        2% of 7% stock 
FCS        10% 
L-glutamine       3g 
The solution was then adjusted to 1L and filtered through a 0.22µm syringe filter. 
4. Tris-EDTA buffer 
Tris-HCl       10mM 
EDTA        1mM 
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5. SDS Loading buffer 
1M Tris, pH 6.8      625µl 
10% SDS       2ml 
2-β-mercaptoethanol      0.5ml 
Glycerol       1ml 
Bromophenol Blue      0.003g 
Top up with double distilled water to 10ml. 
6. ESB solution 
SDS        2% 
Tris pH6.8       80mM 
Glycerol       10% 
DTT        1.5% 
Bromophenol Blue      0.1mg/ml 
7. YPDA/Kan 
Yeast extract       1% 
Peptone       2% 
Dextrose       2% 
Adenine hemisulphate     0.003% 
Kanamycin       15mg/L 
The kanamycin and adenine hemisulphate are filtered sterilized and added to the 
autoclaved solution only after cooling it to below 550C. 
8. PEG/LiAc 
PEG 3350       40% 
Tris-EDTA       1 X 
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Lithium Acetate      1 X 
9. Z buffer (pH7.0) 
Na2HPO4.7H20      16.1g/L 
NaH2PO4.H2O       5.50g/L 
KCl        075g/L 
MgSO4.7H2O       0.246g/L 
10. X-Gal stock solution 
5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal) was dissolved in 
DMF (Sigma-Aldrich) to reach a final concentration of 20mg/ml. 
10. Z buffer / X-Gal solution 
 Z buffer       100ml 
 Β-mercaptoethanol      270µl 
 X-gal stock solution      1.67ml 
11. Fluorescent Dilution Buffer (FDB) 
MgCl2        1mM 
CaCl2        1mM 
Normal porcine serum     5% 
Fetal calf serum      5% 
Bovine serum albumin     2% 
PBS, pH 7.4 
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